

Curriculum Vitae Europass

Informazioni personali

Nome / Cognome	Francesco Dotta	
Indirizzo(i)	Via Salaria 408, 00199 Roma - Italia	
Telefono(i)	+39 0577 232136	Cellulare:
Fax	+39 0577 586186	
E-mail	francesco.dotta@unisi.it	
Cittadinanza	Italiana	
Data di nascita	9 settembre 1960	
Sesso	M	
Codice fiscale	DTTFNC60P09H501W	

Esperienza professionale

2018 -2024	Direttore del Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze, Università di Siena.
2019 ad oggi	Delegato del Rettore alla Sanità
2021 ad oggi	Coordinatore Dottorato di Ricerca in Meidcina Traslazionale e di Precisione, Università di Siena
2023 ad oggi	Componente del Comitato tecnico scientifico dell'Organismo toscano per il governo clinico
2024-	Direttore della Scuola di Specializzazione di Endocrinologia e Malattie del Metabolismo, Università di Siena.
2004-ad oggi	Dirigente Medico di II Livello; Direttore dell'Unità Operativa Complessa di Diabetologia e Malattie Metaboliche , DAI di Scienze Mediche, Azienda Ospedaliera Universitaria Senese.
2018-19	Componente Senato Accademico come rappresentante dei Direttori di Dipartimento Area 2 – Scienze Biomediche e Mediche.
2017-ad oggi	Professore Ordinario , Raggruppamento disciplinare MED/13-Endocrinologia, settore concorsuale 06/D2 Endocrinologia, Nefrologia e Scienze dell'Alimentazione e del Benessere, Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze, Università di Siena.
2015 - 2020	Direttore dell'UOSA di Dietetica Medica , Dipartimento Innovazione, Sperimentazione e Ricerca Clinica e Traslazionale, Azienda Ospedaliera Universitaria Senese.
2014	Abilitazione Scientifica Nazionale settore concorsuale 06/D2 Endocrinologia, Nefrologia e Scienze dell' Alimentazione e del Benessere – I Fascia
2013	Abilitazione Scientifica Nazionale settore concorsuale 06/B1 Medicina Interna – I Fascia
2013-2018	Direttore della Scuola di Specializzazione di Endocrinologia e Malattie del metabolismo, Università di Siena.
2003-2016	Professore Associato Confermato , Raggruppamento disciplinare MED/13-Endocrinologia, Facoltà di Medicina e Chirurgia, Dipartimento di Scienze Mediche Chirurgiche e Neuroscienze, Università di Siena.
2018 ad oggi	Direttore del Centro Studi e Ricerche dell'Health City Institute.
2018- ad oggi	Presidente dell'Osservatorio della Regione Toscana per la formazione medico-specialistica.
2017-2021	Membro del Consiglio Direttivo SIE.

2017-2021	Coordinatore della Commissione Terapie Innovative della SIE.
2017	Membro della Commissione prevista dall'art. 13, comma 4, della LR 40/2005 per il supporto alla predisposizione del protocollo d'intesa tra Regione Toscana e Università.
2014	Membro del Comitato Tecnico Scientifico del CREA Sanità - Consorzio per la Ricerca Economica Applicata in Sanità.
2013 a-2023	Membro del Research Project Review Committee della European Foundation for the Study of Diabetes (EFSD)
2013	Membro dell'Editorial Board dell'American Journal of Clinical and Experimental Immunology.
2013-2015	Membro del Gruppo di lavoro dell'ANVUR per gli Indicatori di terza missione.
2013-2019	Componente della Commissione Relazioni Internazionali per l'Area 2 - Scienze Biomediche e Mediche, Università di Siena.
2012	Co-Direttore de Il Diabete (ISSN:0394-901X).
Dal 2011 - 2018	Academic Editor di PLoS ONE.
Dal 2011 a 2021	Segretario Generale della Commissione Scientifica dell'Italian Barometer Diabetes Observatory.
2011-2015	Membro della Commissione Biologi, Biotecnologi e Corsi Basic Science della Società Italiana di Endocrinologia.
2010-2016	Membro del Gruppo di lavoro sull'internazionalizzazione di Ateneo, Università di Siena.
2010-2012	Coordinatore della Commissione Scientifica della Società Italiana di Diabetologia.
2009 -2011	Membro dell'Editorial Board di Journal of Endocrinological Investigation.
2008-2012	Membro del Consiglio Direttivo della Società Italiana di Diabetologia.
2008-2012	Membro della Commissione Scientifica della Società Italiana di Diabetologia.
2008	Commissario per la valutazione dei Progetti Ordinari di Ricerca del Ministero della Salute.
2008	Referee per la valutazione dei Progetti di Ricerca dell'Istituto Nazionale per la Sanità e Ricerca Medica francese (INSERM).
2007	Referee per la valutazione dei Progetti di Ricerca del Ministero della Ricerca del Belgio.
2007	Membro dell'Editorial Board di Acta Diabetologica.
2007	Commissario per la valutazione dei Progetti Ordinari di Ricerca del Ministero della Salute.
2006-2010	Membro della Commissione per i giudizi di conferma a Professore Associato (Settore MED/13) del Ministero dell'Istruzione, dell'Università e della Ricerca.
Dal 2005 a oggi	Presidente della Fondazione di Ricerca Biomedica "Umberto Di Mario" ONLUS.
2005-2009	Membro dell'Editorial Board di Journal of Clinical Endocrinology and Metabolism.
2005-2010	Associate Editor di Nutrition, Metabolism & Cardiovascular Diseases.
2005-2009	Membro del Medical Science Review Committee, Juvenile Diabetes Research Foundation (JDRF).
2006-2010	Membro e Presidente della Sezione Toscana della Società Italiana di Diabetologia.
2002-2003	Membro della Commissione per i giudizi di conferma a Ricercatore (Settore MED/13) del Ministero dell'Istruzione, dell'Università e della Ricerca.
2002-2006	Membro della Commissione Scientifica della Società Italiana di Diabetologia.
2001-2004	Membro (Executive Officer) del Consiglio Direttivo della Immunology of Diabetes Society (IDS).
1999-2003	Membro del Comitato Scientifico della Fondazione "Promoter - ONLUS", Roma.

- 1999-2002 **Membro** del Comitato di Coordinamento del Gruppo di Studio “Diabete Tipo 1” della Società Italiana di Diabetologia.
- 1999-2001 **Membro** della Commissione Scientifica della Società Italiana di Endocrinologia.
- Dal 1994 a oggi **Membro** del Comitato Scientifico della Fondazione “Diabete Endocrinologia Metabolismo” (DEM), Roma.
- 2000-2003 **Professore Associato**, Raggruppamento disciplinare MED/13-Endocrinologia, I^a Facoltà di Medicina e Chirurgia, Dipartimento di Scienze Cliniche, Università’ degli Studi di Roma “La Sapienza”.
- 1999-2000 **Ricercatore Confermato**, Raggruppamento disciplinare F07E-Endocrinologia, I^a Facoltà di Medicina e Chirurgia, Dipartimento di Scienze Cliniche, Università’ degli Studi di Roma “La Sapienza”.
- 1991-2003 **Dirigente Medico di I livello** presso la Divisione di Endocrinologia, Dipartimento di Scienze Cliniche, Policlinico Umberto I, Università “La Sapienza”, Roma.
- 1990-1999 **Funzionario Tecnico** di ruolo presso la Cattedra di Medicina Costituzionale ed Endocrinologia, Università’ degli Studi di Roma “La Sapienza”.
- 1987-1989 **Ricercatore** in Medicina presso la Harvard University, School of Medicine, Boston, MA - Usa.
- 1986-1989 **Ricercatore** presso il Joslin Diabetes Center, Boston, MA - USA.

Istruzione e formazione

- 1989** Specializzazione in Endocrinologia (70/70 e lode) conseguita presso l’Università’ degli Studi di Roma “La Sapienza”.
- 1986 Abilitazione all’esercizio professionale. Dal 1986 iscritto all’Ordine dei Medici-Chirurghi ed Odontoiatri di Roma.
- 1985 Laurea in Medicina e Chirurgia (110/110 e lode) conseguita presso l’Università’ degli Studi di Roma “La Sapienza” con tesi: “Aspetti immunitari nella gravidanza normale e complicata da diabete”.

Autovalutazione

Livello europeo (*)

Italiano

Inglese

Allegati

Comprensione		Parlato		Scritto	
Ascolto	Lettura	Interazione orale	Produzione orale		
C2	C2	C2	C2	C2	

Principali finanziamenti

Elenco pubblicazioni scientifiche

PRINCIPALI FINANZIAMENTI

- 2022-2026 PNRR D3.4 HEALTH, Ministero dell'Università e della Ricerca.
- 2022-2027 Ministero della Salute: Coordinatore nazionale del Progetto "PUN HUB" Traiettorie 4.
- 2022-2026 PROGETTO PNRR Linea di investimento 1.4. Centri Nazionali, Sviluppo di terapia genica e farmaci con tecnologia a RNA, Ministero dell'Università e della Ricerca. Coordinatore Spoke 5.
- 2020-2024 HEDIMED - Human Exposomic Determinants of Immune Mediated Diseases.
- 2019-2021 INNODIA HARVEST - Translational approaches to disease modifying therapy of type 1 diabetes- HARVESTing the fruits of INNODIA. -
- 2019-2020 JDRF Grant "Collaborative Effort to Identify and Validate miRNA Biomarkers of T1D"
- 2019-2022 Ministero della Salute – Bando Ricerca Finalizzata 2018, Programma di Rete NET 2018 "Precision medicine to target frailty of endocrine-metabolic origin - PROMETEO".
- 2019-2022 PRIN 2017 "Molecular and pathophysiological heterogeneity of autoimmune diabetes: implications for precision medicine".
- 2018 BANDO AIFA 2016-02365049 "Circulating microRNAs and DNA (cfDNA) as novel biomarkers for diagnostic, prognostic and therapeutic use in Medullary Thyroid Carcinoma".
- 2016- PRIN 2015_ "Pancreatic β -cell identity, glucose sensing and the control of insulin secretion".
- 2015-2022 HORIZON 2020-JTI-IMI2-2014-01 of the European Union. "Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes" (INNODIA). **Coordinator of European nPOD Initiative.**
- 2015 Fondazione Roma "Non communicable diseases in the elderly: circulating microRNAs and long non coding RNAs as novel biomarkers of response to therapy in metabolic diseases".
- 2012-2017 National Institutes of Health NIH "Assessment of cytokines in human islets from patients with diabetes".
- 2012- PRIN 2010-2011 "Nuovi aspetti della fisiopatologia del diabete mellito e potenziali applicazioni terapeutiche.
- 2012-2015 Juvenile Diabetes Research Foundation International: nPOD-V "nPOD Viral Work Group".
- 2011-2016 Juvenile Diabetes Research Foundation International: nPOD "Network of pancreatic organ donors".
- 2011-2013 Fondazione CARIPISA "Ruolo del nano incapsulamento mediante multistrati, di nanostrutture con proprietà antiinfiammatorie, e del posizionamento guidato mediante nanoparticelle nel trapianto di isole pancreatiche per il trattamento del diabete di tipo 1".
- 2010-2015 European Community – FP7 PEVNET "Persistent virus infection as a cause of pathogenic inflammation in type 1 diabetes - an innovative research program of biobanks and expertise".
- 2010-2012 Regione Toscana – Programma per la Ricerca regionale in materia di salute 2009 "Pancreatic islet microRNAs as therapeutic target in type 2 diabetes".

- 2010-2012 Fondazione Roma “Molecular mechanisms in the pathogenesis of type 2 diabetes mellitus and its cardiovascular complications”.
- 2010-2012 Fondazione MPS “Screeing per la diagnosi precoce di diabete mellito tipo 1 e di malattia celiaca mediante determinazioni autoanticorpali nella saliva: studio nella popolazione scolastica elementare di Siena”.
- 2009-2012 PRIN 2008 “Verso una terapia cellulare del diabete mellito: Meccanismi molecolari e segnali extracellulari nella regolazione della funzione e della massa cellulare dell'isola pancreatica”.
- 2009-2014 European Community – FP7 NAIMIT “Novel immunotherapies for type 1 diabetes”.

ELENCO PUBBLICAZIONI SCIENTIFICHE

1. Amenta F, Cavallotti C, **Dotta F**, Ferrante F, Spinelli F, Vatrella F. (1983) The autonomic innervation of the human greater saphenous vein. Acta Histochem; 72: 111-116. **(I.F. 2.479)**
2. Di Mario U, Scardellato A, **Dotta F**, Kennedy R, Pozzilli, Andreani D. (1985) T cell phenotype in recent onset and relapsed Graves' disease patients before therapy. In: “Endocrinology '85”. Molinatti GM and Martini L (eds), Elsevier Science Publishers BV: 463-467.
3. Di Mario U, Vitillo M, Cavatorta F, Scardellato A, **Dotta F**, Sutherland J, Pozzilli P, Andreani D. (1986) Monitoring immunopathological events in Graves' patients: humoral vs. cellular immune factors as markers of disease activity. In: “The thyroid and autoimmunity”. Drexhage HA and Wiersinga WM (eds), Elsevier Science Publishers BV: 64-67.
4. Gargiulo P, Di Mario U, **Dotta F**, Kennedy R, Guy K, Pachi A, Fallucca F. (1986) Activated T cells in normal pregnant women and neonates. Eur J Obstet Gyn R B; 23: 127-135. **(I.F. 2.435)**
5. Di Mario U, **Dotta F**, Gargiulo P, Sutherland J, Andreani D, Guy K, Pachi A, Fallucca F. (1987) Immunology in diabetic pregnancy: activated T cells in diabetic mothers and neonates. Diabetologia; 30(2): 66-71. **(I.F. 10.122)**
6. **Dotta F**, Gargiulo P, Tiberti C, Pachi A, Fallucca F, Andreani D, Di Mario U. (1987) Humoral and cellular immune abnormalities in neonates of diabetic mothers: any pathological role? Exp Clin Endocr Diab; 89(3): 333-339. **(I.F. 2.949)**
7. Di Mario U, **Dotta F**, Gargiulo P, Fallucca F, Pachi A, Andreani D. (1987) Immunopathology of diabetic mothers and their infants: a contribution to the understanding of islet autoimmunity. In: “The immunology of diabetes”. Jaworski (ed), Elsevier Science Publisher B.V.: 137-142.
8. Dib SA, Colman PG, **Dotta F**, Tautkus M, Rabizadeh A, Eisenbarth GS. (1987) Expression of cytoplasmic islet cell antigens by rat pancreas. Diabetes; 36(8): 982-985. **(I.F. 9.461)**
9. Di Mario U, Cavatorta F, Scardellato A, **Dotta F**, Vitillo M, Andreani D (1987) Immunological parameters in patients with Graves' disease before treatment. In: Bianchi (ed), “Thyroid function and dysfunction: Modern concepts”, 447- 451.
10. **Dotta F**, Nayak RC, Dib SA, Di Bella E, Krisch K, Posillico JT, Ricker AT, Di Mario U, Eisenbarth GS. (1988) A novel neuroendocrine cell surface glycoprotein: identification, isolation and initial characterization. Endocrinology; 122(4): 1263-1268. **(I.F. 4.736)**

11. Di Mario U, **Dotta F**, Crisa L, Anastasi E, Andreani D, Dib SA, Eisenbarth GS. (1988) Circulating anti-immunoglobulin antibodies in recent-onset type 1 diabetic patients. Diabetes; 37(4): 462-466. **(I.F. 9.461)**
12. Eisenbarth GS, Vardi, Ziegler AG, Colman PG, Nayak RC, **Dotta F**, Jackson RA, Fujii S, Ricker AT, Rabinowe SL, Ikegami H, Soeldner S, Hattori M. (1988) Lessons from the NOD mouse and the BB rat: similarities and contrasts. In: "Animal models in diabetes". Renold AE and Shafir E (eds); John Libbey, London: 120-123.
13. Colman PG, Di Mario U, Rabizadeh A, **Dotta F**, Anastasi E, Eisenbarth GS. (1988) A prozone phenomenon interferes in islet cell antibody detection: direct comparison of two methods in subjects at risk of diabetes and in insulin dependent diabetics at onset. J Autoimmun; 1(2): 109- 117. **(I.F. 7.094)**
14. Dib SA, Colman PG, **Dotta F**, Tautkus M, Rabizadeh A, Eisenbarth GS. (1988) Assay for cytoplasmic islet cell antibodies using two-color immunofluorescence and rat pancreas. Adv Exp Med Biol; 246: 63-67. **(I.F. 2.622)**
15. **Dotta F**, Eisenbarth GS. (1989) Type 1 diabetes mellitus: a predictable autoimmune disease with interindividual variation in the rate of beta cell destruction. Clin Immunol; 50: 85-95. **(I.F. 3.969)**
16. **Dotta F**, Colman PG, Lombardi D, Scharp DW, Andreani D, Pontieri GM, Di Mario U, Lenti L, Eisenbarth GS, Nayak RC. (1989) Ganglioside expression in human pancreatic islets. Diabetes; 38(11): 1478-1483. **(I.F. 9.461)**
17. Gardner SL, **Dotta F**, Nayak RC, George KL, Eisenbarth GS, Halban PA. (1989) Modulation by sodium butyrate of the differentiated status of a clonal pancreatic B-cell line (RIN). Diabetes Res Clin PR; 12(2): 93-99. **(I.F. 5.602)**
18. Russo E, Jackson RA, **Dotta F**, Lipes MA, Castano L, Eisenbarth GS. (1990) Type 1 diabetes as a "Mendelian" and "regulated" immune process. in: "Molecular biology of autoimmunity". A.G. Demaine, J. Banga, A.M.McGregor (eds); Springer-Verlag, London: 351-362.
19. Eisenbarth GS, Jackson RA, Ziegler R, Castano L, Bleich D, **Dotta F**. (1990) Predizione e prevenzione del diabete di tipo 1. Il Diabete; 2: 29-34.
20. **Dotta F**, Pozzilli P. (1990) Are islet cell antigens gangliosides? Intl Diab Monitor; 2: 2-3.
21. Previti M, **Dotta F**, Anastasi E, Gianani R, Lenti L, Pontieri GM, Di Mario U. (1991) Autoimmunità insulare nel ratto BB: I gangliosidi pancreatici del ceppo diabete-prono (DP) differiscono da quelli del diabete-resistente (DR). Il Diabete; 3: 309-311.
22. Anastasi E, Perfetti R, Tiberti C, Crisà L, Cabrera E, **Dotta F**, Di Mario U, Andreani D. (1991) Gli autoanticorpi anti-insulina sono realmente indicatori di diabete mellito di tipo 1? Il Diabete; 3: 357-360.
23. **Dotta F**, Previti M, Lenti L, Tiberti C, Anastasi E, Pontieri GM, Appel MC, Andreani D, Di Mario U (1991) Attività beta cellulare ed espressione antigenica nel pancreas di ratto: identificazione di un ganglioside metabolicamente regolabile. Il Diabete; 3: 365-367.
24. **Dotta F**. (1991) Gangliosidi pancreatici, anticorpi polari ed autoimmunità β cellulare. Il Diabete; 3: 254-257.
25. **Dotta F**. (1991) Anti-glucose transporter molecule(s) autoimmunity in type 1 diabetes? Diab Prev Ther; 5: 3-4.
26. **Dotta F**, Peterson LB, Previti M, Metzger J, Tiberti C, Anastasi E, Zoppitelli, Wicker LS, Di Mario U. (1992) Pancreatic islet ganglioside expression in nonobese diabetic mice: comparison with C57BL/10 mice and changes after autoimmune beta-cell destruction. Endocrinology; 130(1): 37- 42. **(I.F. 4.736)**
27. Rotella C, **Dotta F**, Mannucci E, Di Mario U. (1992) Autoantigens in thyroid and islet autoimmunity: similarities and differences. Autoimmunity; 12(3): 223-237. **(I.F. 2.815)**
28. Previti M, **Dotta F**, Pontieri GM, Di Mario U, Lenti L. (1992) Determination of gangliosides by high-

- performance liquid chromatography with photodiode-array detection. *J Chromatogr A*; 605: 221-225. **(I.F. 4.759)**
29. Wicker LS, Appel MC, **Dotta F**, Pressey A, Miller BJ, DeLarato NH, Fischer PA, Boltz RC, Peterson LB. (1992) Autoimmune syndromes in major histocompatibility complex (MHC) congenic strains of nonobese diabetic (NOD) mice. The NOD MHC is dominant for insulinitis and cyclophosphamide-induced diabetes. *J Exp Med*; 176(1): 67-77. **(I.F. 14.307)**
 30. Pozzilli P, Buzzetti R, **Dotta F**, Andreani D. (1992) Acute onset of seeming IDDM in an AIDS patient. *Diabetes Care*; 15(11): 1824-1825. **(I.F. 19.112)**
 31. Di Mario U, **Dotta F**, Purrello F. (1992) Storia naturale del diabete di tipo 1 in fase preclinica. *Il Diabete*; 4: 283-86.
 32. Cavallo MG, **Dotta F**, Monetini L, Baroni MG, Toto A, Pozzilli P. (1992) Caratterizzazione antigenica di una linea cellulare di insulinoma umano e sua utilizzazione per la valutazione degli anticorpi anti-isola pancreatica. *Il Diabete*; 4, Suppl.1: 71-74.
 33. Previti M, **Dotta F**, Tiberti C, Anastasi E, Lenti L, Pontieri GM, Andreani D, Di Mario U. (1992) Identificazione del ganglioside insulare GM2-1: similitudini con un autoantigene neuronale. *Il Diabete*; 4, Suppl.1: 91-94.
 34. Di Mario U, **Dotta F**. (1992) Natural history and prediction of type 1 diabetes. *Ann Ig*; 4(3): 153-157.
 35. **Dotta F**, Tiberti C, Previti M, Anastasi E, Andreani D, Lenti L, Pontieri GM, Gianani R, Appel MC, Eisenbarth GS, Di Mario U. (1993) Rat pancreatic ganglioside expression: differences between a model of autoimmune islet B cell destruction and a normal strain. *Clin Immunol Immunopathol*; 66(2): 143-149. **(I.F. 3.969)**
 36. Anastasi E, Tiberti C, Sensi M, Ponte E, Filippetti R, **Dotta F**, Vecci E, Fiori MG, Di Mario U. (1993) Pancreatic gangliosides delay the onset of insulinitis and hyperglycaemia in the low-dose streptozotocin mouse model. *Scand J Immunol*; 37(3): 308-313. **(I.F. 3.487)**
 37. **Dotta F**, Dionisi S, Lollobrigida L, Previti M. (1993) Autoanticorpi ed autoantigeni in un modello animale di distruzione β cellulare: il topo NOD. *Giornale It. Diabetol*; Suppl.1: 63-68.
 38. Boccuni ML, Bosi E, Buzzetti R, Calafiore R, Cavallo MG, Di Mario U, **Dotta F**, Giordano C, Pozzilli P, Previti M, Richiusa P, Scorsone A, Signore A, Visalli N. (1993) Immunologia ed immunoterapia del diabete mellito di tipo 1. *Il Diabete*; 5 (Suppl.1): 1-44.
 39. Di Mario U, **Dotta F**. (1993) Modulation of antigen expression in relation to intervention strategies in type 1 diabetes. *Diabetes-Metab Res Rev*; 9(4): 245-249. **(I.F. 4.876)**
 40. La Mancusa R, Alessandri C, Basili S, Violi F, Ferroni P, Gazzaniga PP, Cordova C, **Dotta F**, Tarquini S, Simeoni S, Pettirossi G, Vieri M, Di Palma P, Cara D, Scodanibbio C, Maurelli M, Ferro D, Saliola M, Pulcinelli F, Riondino S. (1994) Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group. *Thromb Haemost*; 72: 343-346. **(I.F. 5.249)**
 41. **Dotta F**, Anastasi E, Tiberti C, Di Mario U. (1994) Autoantigens in type 1 diabetes mellitus. *J Endocrinol Invest*; 17(7): 497-508. **(I.F. 4.256)**
 42. Dionisi S, **Dotta F**. (1994) Can we replace cytoplasmic ICA determination in diabetes prediction? *Diab Prev Ther*; 8: 36-37.
 43. Tiberti C, **Dotta F**, Anastasi E, Torresi P, Multari G, Vecci E, Andreani D, Di Mario U. (1995) Anti-ganglioside antibodies in new onset type 1 diabetic patients and high risk subjects. *Autoimmunity*; 22(1): 43-48. **(I.F. 2.815)**
 44. **Dotta F**, Previti M, Lenti L, Dionisi S, Casetta B, D'Erme M, Eisenbarth GS, Di Mario U. (1995) GM2-1 pancreatic islet ganglioside: identification and characterization of a novel islet-specific molecule. *Diabetologia*; 38(9): 1117-1121. **(I.F. 10.122)**

45. **Dotta F**, Di Mario U. (1996) Antigenic determinants in type 1 diabetes mellitus. Review article. APMIS; 104(11): 769-774. **(I.F. 3.205)**
46. **Dotta F**, Gianani R, Previti M, Lenti L, Dionisi S, D'Erme M, Eisenbarth GS, Di Mario U. (1996) Autoimmunity to the GM2-1 islet ganglioside before and the onset of type 1 diabetes. Diabetes; 45(9): 1193-1196. **(I.F. 9.461)**
47. Mennuni C, Santini C, **Dotta F**, Farilla L, Di Mario U, Fierabracci A, Bottazzo G, Cortese R, Luzzago A. (1996) Selection of phage-displayed peptides mimicking type 1 diabetes-specific epitopes. J Autoimmun; 9(3): 431-436. **(I.F. 7.094)**
48. Cavallo MG, **Dotta F**, Monetini L, Dionisi S, Previti M, Valente L, Toto A, Di Mario U, Pozzilli P. (1996) Beta-cell markers and autoantigen expression by a human insulinoma cell line: similarities to native beta cells. J Endocrinol; 150(1): 113-120. **(I.F. 4.286)**
49. **Dotta F**, Di Mario U. (1996) Il diabete mellito di tipo 1 in Sardegna. Scienza e Diabete; 6: 6-7.
50. **Dotta F**, Dionisi S, Farilla L, Di Mario U. (1996) The use of immunological markers in IDDM after more than 20 years from ICA description. Diabetes-Metab Rev Res; 12(2): 121-126. **(I.F. 4.876)**
51. **Dotta F**, Dionisi S, Misasi R, Tiberti C, Anastasi E, Carabba B, Farilla L, Di Mario U. (1996) Ganglioside antigens in autoimmune diabetes. Diabetes Nutr Metab; 9: 215-220. **(I.F. 0.719)**
52. **Dotta F**. (1996) Highlights from the American Diabetes Association's Symposium on prevention of type 1 diabetes in the general population. Diab Prev Ther; 10: 28-29.
53. Misasi R, Dionisi S, Farilla L, Carabba B, Lenti L, Di Mario U, **Dotta F**. (1997) Gangliosides and autoimmune diabetes. Diabetes-Metab Rev Res; 13(3): 163-179. **(I.F. 4.876)**
54. **Dotta F**, Falorni A, Tiberti C, Dionisi S, Anastasi E, Torresi P, Lernmark A, Di Mario U. (1997) Autoantibodies to the GM2-1 islet ganglioside and to GAD-65 at type 1 diabetes onset. J Autoimmun; 10(6): 585-588. **(I.F. 7.094)**
55. Tiberti C, Falorni A, Torresi P, Vecchi E, Anastasi E, **Dotta F**, Di Mario U. (1997) A new solid-phase radioimmunoassay to detect anti-GAD65 autoantibodies. J Immunol Methods; 207(2): 107-113. **(I.F. 2.303)**
56. Mennuni C, Santini C, Lazzaro D, **Dotta F**, Farilla L, Fierabracci A, Bottazzo GF, Di Mario U, Cortese R, Luzzago A. (1997) Identification of a novel type 1 diabetes-specific epitope by screening phage libraries with sera from pre-diabetic patients. J Mol Biol; 268(3): 599-606. **(I.F. 5.469)**
57. Dionisi S, **Dotta F**, Diaz-Horta O, Carabba B, Viglietta V, Di Mario U. (1997) Target antigens in autoimmune diabetes: pancreatic gangliosides. Ann I Super Sanità; 33(3): 433-435. **(I.F. 1.663)**
58. **Dotta F**, Previti M, Neerman-Arbez M, Dionisi S, Cucinotta D, Lenti L, Di Mario U, Halban PA. (1998) The GM2-1 ganglioside islet autoantigen in insulin-dependent diabetes mellitus is expressed in secretory granules and is not beta-cell specific. Endocrinology; 139(1): 316-319. **(I.F. 4.736)**
59. Di Mario U, **Dotta F**. (1998) Beta-cell autoimmunity 1998. Diabetes-Metab Res Rev; 14(1): 1-2. **(I.F. 4.876)**
60. Anastasi E, **Dotta F**, Tiberti C, Vecchi E, Ponte E, Di Mario U. (1999) Insulin prophylaxis down-regulates islet antigen expression and islet autoimmunity in the low-dose Stz mouse model of diabetes. Autoimmunity; 29(4): 249-256. **(I.F. 2.815)**
61. **Dotta F**, Dionisi S, Viglietta V, Tiberti C, Matteoli MC, Cervoni M, Bizzarri C, Marietti G, Testi M, Multari G, Lucentini L, Di Mario U. (1999) T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus. Eur J Endocrinol; 141(3): 272-278. **(I.F. 6.664)**
62. Anastasi E, Ponte E, Gradini R, Bulotta A, Sale P, Tiberti C, Okamoto H, **Dotta F**, Di Mario U. (1999) Expression of Reg and cytokeratin 20 during ductal cell differentiation and proliferation in a mouse

- model of autoimmune diabetes. Eur J Endocrinol; 141(6): 644-652. **(I.F. 6.664)**
63. **Dotta F**, Santangelo C, Dionisi S, Viglietta V, Vendrame F, Di Mario U. (1999) Linfociti T, autoreattività e apoptosi: basi immunopatogenetiche del diabete di tipo 1. Il Diabete; 11 (Suppl.): 3-5.
64. Tiberti C, Buzzetti R, Anastasi E, **Dotta F**, Vasta M, Petrone A, Cervoni M, Torresi P, Vecci E, Multari G, Di Mario U. (2000) Autoantibody negative new onset of type 1 diabetic patients lacking high risk HLA alleles in a caucasian population: are these type 1b diabetes cases? Diabetes-Metab Res Rev; 16(1): 8-14. **(I.F. 4.876)**
65. Marchetti P, **Dotta F**, Ling Z, Lupi R, Del Guerra S, Santangelo C, Realacci M, Marselli L, Di Mario U, Navalesi R. (2000) Function of pancreatic islets isolated from a type 1 diabetic patient. Diabetes Care; 23(5): 701-703. **(I.F. 19.112)**
66. Cilio CM, Bosco S, Moretti C, Farilla L, Savignoni F, Colarizi P, Multari G, Di Mario U, Bucci G, **Dotta F**. (2000) Congenital autoimmune diabetes mellitus. New Engl J Med; 342(20): 1529-1531. **(I.F. 91.245)**
67. Farilla L, **Dotta F**, Di Mario U, Rapoport B, McLachlan SM. (2000) Presence of interleukin 4 or interleukin 10, but not both cytokines, in pancreatic tissue of two patients with recently diagnosed diabetes mellitus type I. Autoimmunity; 32(3): 161-166. **(I.F. 2.815)**
68. Del Guerra S, Lupi R, **Dotta F**, Marselli L, Lencioni C, Santangelo C, Realacci M, Carmellini M, Mosca F, Navalesi R, Marchetti P. (2000) Effects of prolonged exposure to pancreatic glucagon on the function, antigenicity and survival of isolated human islets. Diabetes-Metab Res Rev; 16(4): 281-286. **(I.F. 4.876)**
69. **Dotta F**. (2000) Meccanismi patogenetici nel diabete autoimmune a lenta insorgenza. Il Diabete; 12: 109-112.
70. Piro S, Lupi R, **Dotta F**, Patané G, Rabuazzo MA, Marselli L, Santangelo C, Realacci M, Del Guerra S, Purrello F, Marchetti P. (2001). Bovine islets are less susceptible than human islets to damage by human cytokines. Transplantation; 71(1): 21-26. **(I.F. 4.939)**
71. Marselli L, **Dotta F**, Piro S, Santangelo C, Masini M, Lupi R, Realacci M, Del Guerra S, Mosca F, Boggi U, Purrello F, Navalesi R, Marchetti P. (2001) Th2 cytokines have a partial, direct protective effect on the function and survival of isolated human islets exposed to combined proinflammatory and Th1 cytokines. J Clin Endocr Metab; 86(10): 4974-4978. **(I.F. 5.958)**
72. Trincavelli ML, Marselli L, Falleni A, Gremigni V, Ragge E, **Dotta F**, Santangelo C, Marchetti P, Lucacchini A, Martini C. (2002) Upregulation of mitochondrial peripheral benzodiazepine receptor expression by cytokine-induced damage of human pancreatic islets. J Cell Biochem; 84(3): 636-644. **(I.F. 4.429)**
73. Miao D, Yu L, Tiberti C, Cuthbertson DD, Rewers M, Di Mario U, Eisenbarth GS, **Dotta F**. (2002) ICA512 (IA-2) epitope specific assays distinguish transient from diabetes associated autoantibodies. J Autoimmun; 18(2): 191-196. **(I.F. 7.094)**
74. **Dotta F**, Vendrame F. (2002) Neonatal syndromes of polyendocrinopathy. Endocrinol Metabol Clin North Amer; 31(2): 283-293. **(I.F. 4.741)**
75. Lupi R, **Dotta F**, Marselli L, Del Guerra S, Masini M, Santangelo C, Patané G, Boggi U, Piro S, Anello M, Bergamini E, Mosca F, Di Mario U, Del Prato S, Marchetti P. (2002) Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes; 51(5): 1437-1442. **(I.F. 9.461)**
76. Farilla L, Tiberti C, Luzzago A, Yu L, Eisenbarth GS, Cortese R, **Dotta F**, Di Mario U. (2002) Application of phage display peptide library to autoimmune diabetes: identification of IA-2/ICA512bdc dominant autoantigenic epitopes. Eur J Immunol; 32(5): 1420-1427. **(I.F. 5.532)**
77. **Dotta F**, Anastasi E. (2002) Nuove fonti di cellule producenti insulina. Il Diabete; 14: 128-133.

78. Davidson J, Wilkinson A, Dantal J, **Dotta F**, Haller H, Hernandez D, Kasiske BL, Kiberd B, Krentz A, Legendre C, Marchetti P, Markell M, van der Woude FJ, Wheeler DC; International Expert Panel. (2003) New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an International expert panel meeting. Barcelona, Spain, 19 february 2003. Transplantation; 75(10): 3-24. **(I.F. 4.939)**
79. Tiberti C, Bao F, Bonamico M, Verrienti A, Picarelli A, Di Tola M, Ferri M, Vecci E, **Dotta F**, Eisenbarth GS, Di Mario U. (2003) Celiac disease-associated transglutaminase autoantibody target domains at diagnosis are age and sex dependent. Clin Immunol Immunopathol; 109(3): 318-324. **(I.F. 3.969)**
80. Lupi R, Marselli L, Dionisi S, Del Guerra S, Boggi U, Del Chiaro M, Lencioni C, Bugliani M, Mosca F, Di Mario U, Del Prato S, **Dotta F**, Marchetti P. (2004) Improved insulin secretory function and reduced chemotactic properties after tissue culture of islets from type 1 diabetic patients. Diabetes-Metab Res Rev; 20(3): 246-251. **(I.F. 4.876)**
81. Hui H, **Dotta F**, Di Mario U, Perfetti R. (2004) Role of caspases in the regulation of apoptotic pancreatic islet beta-cells death. J Cell Physiol; 200(2): 177-200. **(I.F. 6.384)**
82. Falorni A, Laureti S, De Bellis A, Zanchetta R, Tiberti C, Arnaldi G, Bini V, Beck-Peccoz P, Bizzarro A, **Dotta F**, Mantero F, Bellastella A, Betterle C, Santeusano F; SIE Addison Study Group. (2004) Italian addison network study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. J Clin Endocr Metab; 89(4): 1598-1604. **(I.F. 5.958)**
83. Marselli L, Trincavelli L, Santangelo C, Lupi R, Del Guerra S, Boggi U, Falleni A, Gremigni V, Mosca F, Martini C, **Dotta F**, Di Mario U, Del Prato S, Marchetti P. (2004) The role of peripheral benzodiazepine receptors on the function and survival of isolated human pancreatic islets. Eur J Endocrinol; 151(2): 207-214. **(I.F. 6.664)**
84. **Dotta F**, Marchetti P. (2004) Pathological changes in human insulinitis. Curr Opin Endocrinol Diabetes Obes; 11: 82-84. **(I.F. 3.243)**
85. Vendrame F, Zappaterreno A, **Dotta F**. (2004) Markers of beta cell function in type 1 diabetes mellitus. Minerva Med; 95(2): 79-84. **(I.F. 4.806)**
86. Vendrame F, Santangelo C, Misasi R, Dionisi S, Gizzi C, Realacci M, Grassetti D, Di Mario U, **Dotta F**. (2005) Defective lymphocyte caspase-3 expression in type 1 diabetes mellitus. Eur J Endocrinol; 152(1): 119-125. **(I.F. 6.664)**
87. Santangelo C, Scipioni A, Marselli L, Marchetti P, **Dotta F**. (2005) Suppressor of cytokine signaling gene expression in human pancreatic islets: modulation by cytokines. Eur J Endocrinol; 152(3): 485-489. **(I.F. 6.664)**
88. Putnam AL, Vendrame F, **Dotta F**, Gottlieb PA. (2005) CD4+CD25 high regulatory T cells in human autoimmune diabetes. J Autoimmun; 24(1): 55-62. **(I.F. 7.094)**
89. Tiberti C, Verrienti A, Fiore B, Yu L, Eisenbarth GS, **Dotta F**, Di Mario U. (2005) IA-2 combined epitope assay: a new, highly sensitive approach to evaluate IA-2 humoral autoimmunity in type 1 diabetes. Clin Immunol; 115(3): 260-267. **(I.F. 3.969)**
90. Anastasi E, Santangelo C, Bulotta A, **Dotta F**, Argenti B, Mincione C, Gulino A, Maroder M, Perfetti R, Di Mario U. (2005) The acquisition of an insulin-secreting phenotype by HGF-treated rat pancreatic ductal cells (ARIP) is associated with the development of susceptibility to cytokine-induced apoptosis. J Mol Endocrinol; 34(2): 367-376. **(I.F. 5.098)**
91. Wilkinson A, Davidson J, **Dotta F**, Home P, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregrosa JV, Uchida K, Valentine F, Villamil F, Vincenti F, Wissing M. (2005) Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant; 19(3): 291-298. **(I.F. 2.863)**

92. Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, Marzotti S, Corneli RB, Ferretti E, Gulino A, Grasso F, De Simone C, Di Mario U, Falorni A, Boirivant, **Dotta F**. (2005) Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia; 48(8): 1565-1575. **(I.F. 10.122)**
93. **Dotta F**, Fondelli C, Vendrame F, Gianani R. (2005) Pathological changes in human islets. Curr Opin Endocrinol Diabetes Obes; 12: 285-290. **(I.F. 3.243)**
94. Fourlanos S, **Dotta F**, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, Harrison LC. (2005) Latent Autoimmune Diabetes in Adults (LADA) should be less latent. Diabetologia; 48(11): 2206-2212. **(I.F. 10.122)**
95. **Dotta F**, Fondelli C, Di Mario U. (2005) Type 1 diabetes mellitus as a polygenic multifactorial disease: immunopathogenic mechanisms of beta-cell destruction. Acta Biomed; 76 Suppl 3: 14-18.
96. Roep B, Van Halteren A, Boggi U, Marchetti P, **Dotta F**. (2005) Islet autoreactivity in pancreas draining lymph nodes in recent onset type 1 diabetes. Endocr J; 52: 162-164. **(I.F. 2.349)**
97. Tiberti C, Bonamico M, **Dotta F**, Verrienti A, Di Tola M, Liu E, Ferri M, Nenna R, Picarelli A, Eisenbarth GS. (2006) Evidence of a selective epitope loss of anti-transglutaminase immunoreactivity in gluten-free diet celiac sera: a new tool to distinguish disease-specific immunoreactivities. Clin Immunol; 121(1): 40-46. **(I.F. 3.969)**
98. Vendrame F, Segni M, Grassetto D, Tellone V, Augello G, Trischitta V, Torlontano M, **Dotta F**. (2006) Impaired caspase-3 expression by peripheral T cells in chronic autoimmune thyroiditis and in autoimmune polyendocrine syndrome-2. J Clin Endocr Metab; 91(12): 5064-5068. **(I.F. 5.958)**
99. **Dotta F**, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S, Mosca F, Boggi U, Onetti Muda A, Del Prato S, Elliott JF, Covacci A, Rappuoli R, Roep BO, Marchetti P. (2007) Coxsackie B4 virus infection of beta cells and natural killer cell insulinitis in recent-onset type 1 diabetic patients. P Natl Acad Sci USA; 104(12): 5115-5120. **(I.F. 11.205)**
100. Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, Capizzi M, Arpi ML Bazzigaluppi E, **Dotta F**, Bosi E. (2007) High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care; 30(4): 932-938. **(I.F. 19.112)**
101. Gallo R, Gambelli F, Gava B, Sasdelli F, Tellone V, Masini M, Marchetti P, **Dotta F**, Sorrentino V. (2007) Generation and expansion of multipotent mesenchymal progenitor cells from cultured human pancreatic islets. Cell Death Differ; 14(11): 1860-1871. **(I.F. 15.828)**
102. Giannakakis K, Massella L, Grassetto D, **Dotta F**, Perez M, Onetti-Muda A. (2007) Type VII collagen in Alport syndrome. Nephrol Dial Transplant; 22(12): 3501-3507. **(I.F. 5.992)**
103. Marchetti P, **Dotta F**, Lauro D, Purrello F. (2008) An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. Peptides; 146(1-3): 4-11. **(I.F. 3.750)**
104. Bolli G, **Dotta F**, Rochotte E, Cohen SE. (2008) Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab; 10(1): 82-90. **(I.F. 6.577)**
105. Egan CG, Lavery R, Caporali F, Fondelli C, Laghi-Pasini F, **Dotta F**, Sorrentino V. (2008) Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia; 51(7): 1296-1305. **(I.F. 10.122)**
106. Vendrame F, Verrienti A, Parlapiano C, Filetti S, **Dotta F**, Morano S. (2008) Thyrotoxic periodic paralysis in an Italian man: clinical manifestation and genetic analysis. Ann Clin Biochem; 45(Pt 2): 218-220. **(I.F. 2.057)**
107. Tiberti C, Giordano C, Locatelli M, Bosi E, Bottazzo GF, Buzzetti R, Cucinotta D, Galluzzo A, Falorni A, **Dotta F**. (2008) Identification of tyrosine phosphatase 2 (256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring

- autoimmune diabetes (NIRAD) study 2. *Diabetes*; 57(5): 1276-1283. **(I.F. 9.461)**
108. Bonato V, Barni R, Cataldo D, Collini A, Ruggieri G, De Bartolomeis C, **Dotta F**, Carmellini M. (2008) Analysis of posttransplant diabetes mellitus prevalence in a population of kidney transplant recipients. *Transpl P*; 40(6): 1888-1890. **(I.F. 1.066)**
 109. Bruno G, De Micheli G, Fedele D, Monge L, Bonomo M, Consoli A, De Cosmo S, Di Bartolo P, Di Benedetto A, Di Cianni G, **Dotta F**, Giaccari A, Giorgino F, Grassi G, Gruden G, Mannino D, Orlandini D, Ponziani MC, Vaccaro O, Vitacolonna E. (2008) Italian standards for diabetes mellitus 2007: executive summary. *Acta Diabetol*; 45: 107-127. **(I.F. 4.280)**
 110. Gallo R, Grieco FA, Marselli L, Ferretti E, Gulino A, Marchetti P, **Dotta F**. (2008) Hedgehog signaling during expansion of human pancreatic islet-derived precursors. *Ann NY Acad Sci*; 1150: 43-45. **(I.F. 5.691)**
 111. **Dotta F**, Fondelli C, Falorni A. (2008) Can NK cells be a therapeutic target in human type 1 diabetes? *Eur J Immunol*; 38(11): 2961-2963. **(I.F. 5.532)**
 112. **Dotta F**. (2009) Innate immunity and human insulinitis during beta-cell Coxsackie B4 infection. *J Med Virol*; 81: 202. **(I.F. 2.327)**
 113. Tiberti C, Shashaj B, Verrienti A, Vecci EG, Lucantoni F, Masotti D, Morano S, Sulli N, **Dotta F**. (2009) GAD and IA-2 autoantibody detection in type 1 diabetic patient saliva. *Clin Immunol*; 131(2): 271-276. **(I.F. 3.969)**
 114. Bosi E, **Dotta F**, Jia Y, Goodman M. (2009) Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. *Diabetes Obes Metab*; 11(5): 506-515. **(I.F. 6.577)**
 115. Bolli G, **Dotta F**, Colin L, Minic B, Goodman M. (2009) Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. *Diabetes Obes Metab*; 11(6): 589-595. **(I.F. 6.577)**
 116. Bonato V, Cataldo D, **Dotta F**, Carmellini M. (2009) Diagnosis and approach to posttransplant diabetes. *Curr Diabetes Rep*; 9(4): 317-323. **(I.F. 4.810)**
 117. La Marca A, Marzotti S, Brozzetti A, Stabile G, Artensio AC, Bini V, Giordano R, De Bellis A, Volpe A, Falorni A; Italian Addison Network. (2009) Primary ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles. *J Clin Endocr Metab*; 94(10): 3816-23. **(I.F. 5.958)**
 118. Brozzetti A, Marzotti S, Tortoioli C, Bini V, Giordano R, **Dotta F**, Betterle C, De Bellis A, Arnaldi G, Toscano V, Arvat E, Bellastella A, Mantero F, Falorni A; Italian Addison Network. (2010) Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies. *Eur J Endocrinol*; 162(2): 361-369. **(I.F. 6.664)**
 119. Roep BO, Kleijwegt FS, van Halteren AG, Bonato V, Boggi U, Vendrame F, Marchetti P, **Dotta F**. (2010) Islet inflammation and CXCL10 in recent-onset type 1 diabetes. *Clin Exp Immunol*; 159(3): 338-343. **(I.F. 4.330)**
 120. Igoillo-Esteve M, Marselli L, Cunha DA, Ladrière L, Ortis F, Grieco FA, **Dotta F**, Weir GC, Marchetti P, Eizirik DL, Cnop M. (2010) Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. *Diabetologia*; 53(7): 1395-1405. **(I.F. 10.122)**
 121. **Dotta F**, Galleri L, Sebastiani G, Vendrame F. (2010) Virus infections: lessons from pancreas histology. *Curr Diabetes Rep*; 10(5): 357-361. **(I.F. 4.810)**
 122. Olivieri A, De Angelis S, Dionisi S, D'Annunzio G, Locatelli M, Marinaro M, Bonato V, Amendola A, Songini M, Velluzzi F, Schirru C, Cotichini R, Stazi MA, **Dotta F**, Lorini R, Bottazzo GF, Boirivant

- M. (2010) Serum transforming growth factor β 1 during diabetes development in non-obese diabetic mice and humans. *Clin Exp Immunol*; 162(3): 407-414. **(I.F. 4.330)**
123. Merlotti D, Gennari L, **Dotta F**, Lauro D, Nuti R. (2010) Mechanisms of impaired bone strength in type 1 and 2 diabetes. *Nutr Metab Cardiovas Dis*; 20(9): 683-690. **(I.F. 4.222)**
124. Gallwitz B, Haupt A, Kraus P, Peters N, Petto H, **Dotta F**, Petto H, Poll L, Rose L, Schernthaner G. (2010) Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al. *Diabetes Obes Metab*; 12(12): 1127-1128. **(I.F. 6.577)**
125. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M; 1860-LIRA-DPP-4 Study Group. (2010) Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. *Lancet*. 2010 Apr 24; 375(9724):1447-56. Erratum in: *Lancet*. 2010 Jul 24;376(9737):234. **(I.F. 79.321)**
126. Grieco FA, Vendrame F, Spagnuolo I, **Dotta F**. (2011) Innate immunity and the pathogenesis of type 1 diabetes. *Semin Immunopathol*; 33(1): 57-66. **(I.F. 9.623)**
127. Sebastiani G, Vendrame F, **Dotta F**. (2011) MicroRNAs as new tools for exploring type 1 diabetes: relevance for immunomodulation and transplantation therapy. *Transpl P*; 43(1): 330-332. **(I.F. 1.066)**
128. Falorni A, Chen S, Zanchetta R, Yu L, Tiberti C, Bacosi ML, Furmaniak J, Bini V, **Dotta F**, Eisenbarth GS, Smith BR, Betterle C. (2011) Measuring adrenal autoantibody response: interlaboratory concordance in the first international serum exchange for the determination of 21-hydroxylase autoantibodies. *Clin Immunol*; 140(3): 291-299. **(I.F. 3.969)**
129. Sebastiani G, Grieco FA, Spagnuolo I, Galleri L, Cataldo D, **Dotta F**. (2011) Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. *Diabetes-Metab Res Rev*; 27(8): 862-866. **(I.F. 4.876)**
130. Grieco FA, Moretti M, Sebastiani G, Galleri L, Spagnuolo I, Scafetta G, Gulino A, De Smaele E, Maroder M, **Dotta F**. (2011) Delta-cell specific expression of hedgehog pathway Ptch1 receptor in murine and human endocrine pancreas. *Diabetes-Metab Res Rev*; 27(8): 755-760. **(I.F. 4.876)**
131. Bruno G, De Micheli A, Frontoni S, Monge L, Bonomo M, De Cosmo S, Grassi G, Nicolucci A, Aiello A, Bertuzzi F, Bonora E, Cimino A, Cordera R, de Bigontina G, Di Bartolo P, **Dotta F**, Frittitta L, Giaccari A, Giorgino F, Gruden G, Marchetti P, Meschi F, Pellegrini MA, Rivellese A, Sesti G. (2011) Highlights from "Italian Standards of care for Diabetes Mellitus 2009-2010". *Nutr Metab Cardiovas Dis*; 21(4): 302-314. **(I.F. 4.222)**
132. Tancredi M, Marselli L, Lencioni C, Masini M, Bugliani M, Suleiman M, Masiello P, Boggi U, Filipponi F, **Dotta F**, Marchetti P, Di Cianni G. (2011) Histopathology and ex vivo insulin secretion of pancreatic islets in gestational diabetes: A case report. *Islets*; 3(5): 231-233. **(I.F. 2.694)**
133. Tiberti C, Yu L, Lucantoni F, Panimolle F, Spagnuolo I, Lenzi A, Eisenbarth GS, **Dotta F**. (2011) Detection of four diabetes specific autoantibodies in a single radioimmunoassay: an innovative high-throughput approach for autoimmune diabetes screening. *Clin Exp Immunol*; 166(3): 317-324. **(I.F. 4.330)**
134. Vendrame F, **Dotta F**. (2011) Comment on: Meagher et al. Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism. *Diabetes* 2010;59:2862-2871. *Diabetes*; 60(2): e12. **(I.F. 9.461)**
135. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Cavalot F, Cignarelli M, Laviola L, Morano S, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. (2011) Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. *J Hypertens*; 29(9): 1802-9. **(I.F. 4.844)**
136. Nicolucci A, Del Prato S, Vespasiani G; ELEONOR Study Group. (2011) Optimizing insulin glargine

- plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction. *Diabetes Care*; 34(12): 2524-6. **(I.F. 19.112)**
137. Grieco FA, Sebastiani G, Spagnuolo I, Patti A, **Dotta F.** (2012) Immunology in the clinic review series; focus on type 1 diabetes and viruses: how viral infections modulate beta cell function. *Clin Exp Immunol*; 168(1): 24-29. **(I.F. 4.330)**
138. Vendrame F, Cataldo D, Ciarlo L, Umland O, Misasi R, **Dotta F.** (2012) In type 1 diabetes immunocompetent cells are defective in IL-16 secretion. *Scand J Immunol*; 75(1): 127-128. **(I.F. 3.487)**
139. Coppieters KT, **Dotta F,** Amirian N, Campbell PD, Kay TW, Atkinson MA, Roep BO, von Herrath MG. (2012) Demonstration of islet-autoreactive CD8 T cells in insulinitic lesions from recent onset and long-term type 1 diabetes patients. *J Exp Med*; 209(1): 51-60. **(I.F. 14.307)**
140. Del Prato S, Nicolucci A, Lovagnini-Scher AC, Turco S, Leotta S, Vespasiani G; ELEONOR Study Group. (2012) Telecare Provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine-the ELEONOR study. *Diabetes Technol Ther*; 14(2): 175-82. **(I.F. 6.118)**
141. Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M, Wolka AM, Boardman MK; DURATION-4 Study Group (2012) Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. *Diabetes Care*; 35(2): 252-8. **(I.F. 19.112)**
142. Gallo R, Natale M, Vendrame F, Boggi U, Filipponi F, Marchetti P, Laghi Pasini F, **Dotta F.** (2012) In vitro effects of mycophenolic acid on survival, function, and gene expression of pancreatic beta-cells. *Acta Diabetol*; 49 Suppl 1: S123-31. PMID: 22249339. **(I.F. 4.280)**
143. Guarino E, Nigi L, Patti A, Fondelli C, **Dotta F.** (2012) Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. *Expert Opin Pharmacother*; 13(9): 1377-84. **(I.F. 3.889)**
144. Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabrò A, Cataldo D, Stolakis K, **Dotta F,** Nuti R. (2012) Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. *J Clin Endocr Metab*; 97(5): 1737-1744. **(I.F. 5.958)**
145. Takiishi T, Korf H, Van Belle TL, Robert S, Grieco FA, Caluwaerts S, Galleri L, Spagnuolo I, Steidler L, Van Huynegem K, Demetter P, Wasserfall C, Atkinson MA, **Dotta F,** Rottiers P, Gysemans C, Mathieu C. (2012) Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified *Lactococcus lactis* in mice. *J Clin Invest*; 122(5): 1717-1725. **(I.F. 14.808)**
146. Gallwitz B, Guzman J, **Dotta F,** Guerci B, Simò R, Basson BR, Festa A, Kiljanski J, Sapin H, Trautmann M, Schernthaner G. (2012) Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. *Lancet*; 379(9833): 2270-2278. **(I.F. 79.321)**
147. Marchetti P, Lupi R, Bugliani M, Kirkpatrick CL, Sebastiani G, Grieco FA, Del Guerra S, D'Aleo V, Piro S, Marselli L, Boggi U, Filipponi F, Tinti L, Salvini L, Wollheim CB, Purrello F, **Dotta F.** (2012) A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. *Diabetologia*; 55(12): 3262-3272. **(I.F. 10.122)**
148. Galleri L, Sebastiani G, Vendrame F, Grieco FA, Spagnuolo I, **Dotta F.** (2012) Viral Infections and Diabetes. *Adv Exp Med Biol*; 771: 252-271. **(I.F. 2.622)**
149. Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Maggioni AP, Mocarelli P, Nicolucci A, Rivellese AA, Squatrito S, Riccardi G; TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial). (2012) Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. *Nutr Metab Cardiovas Dis*; 22(11): 997-1006. **(I.F. 4.222)**

150. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaidis M, Richard A, Xiang Z, Brunel P, Pfeffer MA, ALTITUDE Investigators (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. New Engl J Med; 367(23): 2204-13. **(I.F. 91.245)**
151. Rissanen A, Howard CP, Botha J, Thuren T, for the Global Investigators (2012) Effect of anti-IL-1 β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metab; 14:1088-1096. **(I.F. 6.577)**
152. Valle A, Giamporcaro GM, Scavini M, Stabilini A, Grogan P, Bianconi E, Sebastiani G, Masini M, Maugeri N, Porretti L, Bonfanti R, Meschi F, De Pellegrin M, Lesma A, Rossini S, Piemonti L, Marchetti P, **Dotta F**, Bosi E, Battaglia M. (2013) Reduced circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes; 62(6): 2072-77. **(I.F. 9.461)**
153. Sebastiani G, Nigi L, Spagnuolo I, Morganti E, Fondelli C, **Dotta F**. (2013) MicroRNA profiling in sera of patients with type 2 diabetes mellitus reveals an upregulation of miR-31 expression in subjects with microvascular complications. J Biomedical Science and Engineering (JBiSE); 6: 58-64.
154. Tortosa F, **Dotta F**. (2013) Incretin hormones and beta-cell mass expansion: what we know and what is missing? Arch Physiol Biochem; 119(4):161-169. **(I.F. 4.076)**
155. Patti A, Gennari L, Merlotti D, **Dotta F**, Nuti R. (2013) Endocrine actions of osteocalcin. Int J Endocrinol; 2013:846480. **(I.F. 3.257)**
156. Spagnuolo I, Patti A, Sebastiani G, Nigi L, **Dotta F**. (2013) The case for virus-induced type 1 diabetes. Curr Opin Endocrinol Diabetes Obes; 20(4):292-8. **(I.F. 3.243)**
157. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Morano S, Cavalot F, Lamacchia O, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events Study Group. (2013) HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. Diabetes care; 36(8): 2301-10. **(I.F. 19.112)**
158. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) study group. (2013) Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the RIACE Italian multicentre study. J Intern Med; 274(2): 176-191. **(I.F. 8.989)**
159. Bosi E, Scavini M, Ceriello A, Cucinotta D, Tiengo A, Marino R, Bonizzoni E, Giorgino F; PRISMA Study Group. (2013) Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: the PRISMA randomized trial. Diabetes Care; 36(10): 2887-94. **(I.F. 19.112)**
160. Ceccarelli E, Guarino E, Merlotti D, Patti A, Gennari L, Nuti R, **Dotta F**. (2013) Beyond glycemic control in diabetes mellitus: effects of incretin-based therapy on bone metabolism. Front Endocrinol; doi:10.3389/fendo.2013.00073; 4(73): 1-12. **(I.F. 5.555)**
161. Grieco FA, Moore F, Vigneron F, Santin I, Villate O, Marselli L, Rondas D, Overbergh L, **Dotta F**, Marchetti P, Mathieu C, Eizirik DL. (2013) Il-17A increases the expression of pro-inflammatory chemokines in human pancreatic islets. Diabetologia; 57(3): 502-511. **(I.F. 10.122)**
162. Mannucci E, Genovese S, Monami M, Navalesi G, **Dotta F**, Anichini R, Romagnoli F, Gensini G. (2014) Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled study. The D.A.N.T.E. (Diabetic ulcer Antimicrobial New Topical treatment Evaluation) Study. Acta Diabetol; 51(3): 435-40. **(I.F. 4.280)**
163. Tiberti C, Panimolle F, Bonamico M, Filardi T, Pallotta L, Nenna R, Pontone S, **Dotta F**, Pugliese G, Lenzi A, Balducci S, Morano S. (2014) Long-standing type 1 diabetes: patients with adult-onset develop celiac-specific immunoreactivity more frequently than patients with childhood-onset diabetes, in a

- disease duration-dependent manner. *Acta Diabetol*; 51(4):675-8. (I.F. 4.280)
164. **Dotta F**, Sebastiani G. (2014) Enteroviral infections and development of type 1 diabetes: The Brothers Karamazov within the CVBs. *Diabetes*; 63(2): 384-6. (I.F. 9.461)
 165. Takiishi T, Ding L, Baeke F, Spagnuolo I, Sebastiani G, Laureys J, Verstuyf A, Carmeliet G, **Dotta F**, Van Belle T, Gysemans C, Mathieu C. (2014)^[1]_[SEP] Dietary supplementation with high doses of regular vitamin D3 safely reduces Diabetes incidence in nod mice when given early and long-term. *Diabetes*; 63(6): 2026-36. (I.F. 9.461)
 166. Robert S, Gysemans C, Takiishi T, Korf H, Spagnuolo I, Sebastiani G, Van Huynegem K, Steidler L, Caluwaerts S, Demetter P, Wasserfall CH, Atkinson MA, **Dotta F**, Rottiers P, Van Belle TL, Mathieu C. (2014) Oral delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by *Lactococcus lactis* reverses diabetes in recent-onset NOD mice. *Diabetes*; 63(8): 2876-87. (I.F. 9.461)
 167. Pugliese G, Solini A, Bonora E, Orsi E, Zerbini G, Fondelli C, Gruden G, Cavalot F, Lamacchia O, Trevisan R, Vedovato M, Penno G; RIACE Study Group. (2014) Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. *Cardiovasc Diabetol*;13(1): 59. (I.F. 9.951)
 168. Cantara S, Pilli T, Sebastiani G, Cevenini G, Busonero G, Cardinale S, **Dotta F**, Pacini F. (2014) Circulating miRNA95 and miRNA190 are sensitive markers for the differential diagnosis of thyroid nodules in a Caucasian population. *J Clin Endocr Metab*; 99(11):4190-8. (I.F. 5.958)
 169. Pugliese G, Solini A, Bonora E, Fondelli C, Orsi E, Nicolucci A, Penno G, RIACE Study Group. (2014) Chronic kidney disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. *Nutr Metab Cardiovas Dis*; 24(8): 815-22. (I.F. 4.222)
 170. Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E, Figueroa K, Jiang J, Law G, Usiskin K, Meininger G; DIA3004 Study Group. (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. *Diabetes Obes Metab*; 16(10):1016-27. (I.F. 6.577)
 171. Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; NN9068-3697 (DUAL-I) trial investigators. (2014) Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. *Lancet Diabetes Endocrinol*; 2(11):885-93. (I.F. 32.069)
 172. Zampetti S, Campagna G, Tiberti C, Songini M, Arpi ML, De Simone G, Cossu E, Cocco L, Osborn J, Bosi E, Giorgino F, Spoletini M, Buzzetti R; NIRAD Study Group. (2014) High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7). *Eur J Endocrinol*; 171(6):697-704. (I.F. 6.664)
 173. Mathieu C, Overbergh L, Badenhoop K, Bingley P, Dayan C, Demengeot J, **Dotta F**, Eizirik D, Lenzen S, Marchetti P, Peakman M, Roep B, Todd J, Rottiers P, Megit S. (2014) The story of NAIMIT – A framework 7 project on type 1 diabetes. *Eur Endocrinol*; 10(2):100-105.
 174. Sebastiani G, Po A, Miele E, Ventriglia G, Ceccarelli E, Bugliani M, Marselli L, Marchetti P, Gulino A, Ferretti E, **Dotta F**. (2015) MicroRNA-124a is hyperexpressed in type-2 diabetic human pancreatic islets and negatively regulates insulin secretion. *Acta Diabetol*; 52(3):523-30. (I.F. 4.280)
 175. Buzzetti R, Spoletini ML, Zampetti S, Campagna G, Marandola L, Panimolle F, **Dotta F**, Tiberti C for the NIRAD Study Group (NIRAD 8). (2015) Tyrosine phosphatase-related islet antigen 2₍₂₅₆₋₇₆₀₎ autoantibodies, the only marker of islet autoimmunity that increases by increasing the degree of BMI in obese subjects with type 2 diabetes. *Diabetes Care*; 38(3):513-20. (I.F. 19.112)
 176. Nicolucci A, Pintaudi B, Rossi MC, Messina R, **Dotta F**, Frontoni S, Caputo S, Lauro R. (2015) The social burden of Hypoglycemia in the elderly. *Acta Diabetol*; 52(4):677-85. (I.F. 4.280)

177. Pellegrini S, Ungaro F, Mercalli A, Melzi R, Sebastiani G, **Dotta F**, Broccoli V, Piemonti L, Sordi V. (2015) Human induced pluripotent stem cells differentiate into insulin-producing cells able to engraft in vivo. Acta Diabetol; 52(6):1025-35. **(I.F. 4.280)**
178. Schernthaner G, Rosas-Guzmán J, **Dotta F**, Guerci B, Simó R, Festa A, Kiljański J, Zhou M, Gallwitz B. (2015) Treatment escalation options for patients with type 2 diabetes after failure of exenatide BID or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) Study. Diabetes Obes Metab; 17(7):689-698. **(I.F. 6.577)**
179. Ventriglia G, Nigi L, Sebastiani G, **Dotta F**. (2015) MicroRNAs: novel players in the dialogue between pancreatic islets and immune system in autoimmune diabetes. Biomed Res Int; 2015:749734. **(I.F. 3.411)**
180. Sebastiani G, Mancarella F, Ventriglia G, Nigi L, Valentini M, Grieco GE, **Dotta F**. (2015) MicroRNA miR-124a, a negative regulator of insulin secretion, is hyperexpressed in human pancreatic islets of type 2 diabetic patients. RNA & DISEASE; 2: e593. DOI: 10.14800/rd.593.
181. Simó R, Guerci B, Schernthaner G, Gallwitz B, Rosas-Guzmán J, **Dotta F**, Festa A, Zhou M, Kiljański J. (2015) Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovasc Diabetol; 14:116. DOI 10.1186/s12933-015-0279-z. **(I.F. 9.951)**
182. Martino L, Masini M, Bugliani M, Marselli L, Suleiman M, Boggi U, Nogueira TC, Filipponi F, Occhipinti M, Campani D, **Dotta F**, Syed F, Eizirik DL, Marchetti P, De Tata V. (2015) Mast cells infiltrate pancreatic islets in human type 1 diabetes. Diabetologia; 58(11):2554-62. **(I.F. 10.122)**
183. Battaglia M, Nigi L, **Dotta F**. (2015) Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset? Curr Diabetes Rep; 15(12):115. doi: 10.1007/s11892-015-0690-6. **(I.F. 4.810)**
184. Belba A, Cortelazzo A, Giansanti A, Durante J, Nigi L, **Dotta F**, Timperio AM, Zolla L, Leoncini R, Guerranti R, Ponchietti R. (2016) Erectile dysfunction and diabetes: association with the impairment of lipid metabolism and oxidative Stress. Clin Biochem; 49(1):70-8. **(I.F. 3.281)**
185. Laiho JE, Oikarinen M, Richardson SJ, Frisk G, Nyalwidhe J, Burch TC, Morris MA, Oikarinen S, Pugliese A, **Dotta F**, Campbell-Thompson M, Nadler J, Morgan NG, Hyöty H, JDRF nPOD-Virus Group. (2016) Relative sensitivity of immunohistochemistry, multiple reaction monitoring mass spectrometry, *in situ* hybridization and PCR to detect Coxsackievirus B1 in A549 cells. J Clin Virol; 77:21-8. doi: 10.1016/j.jcv.2016.01.015. **(I.F. 3.168)**
186. Grieco FA, Sebastiani G, Juan-Mateu J, Villate O, Marroqui L, Ladrière L, Tugay K, Regazzi R, Bugliani M, Marchetti P, **Dotta F**, Eizirik DL. (2016) MicroRNAs miR-23a-3p, miR-23b-3p and miR-149-5p Regulate the Expression of Pro-Apoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic Beta Cells. Diabetes; 66(1):100-112. **(I.F. 9.461)**
187. Vitale M, Masulli M, Rivellese AA, Bonora E, Cappellini F, Nicolucci A, Squatrito S, Antenucci D, Barrea A, Bianchi C, Bianchini F, Fontana L, Fornengo P, Giorgino F, Gnasso A, Mannucci E, Mazzotti A, Nappo R, Palena AP, Pata P, Perriello G, Potenziani S, Radin R, Ricci L, Romeo F, Santini C, Scarponi M, Serra R, Timi A, Turco AA, Vedovato M, Zavaroni D, Grioni S, Riccardi G, Vaccaro O; TOSCA.IT Study Group. (2016) Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study. Eur J Nutr; 57(2):679-688. doi: 10.1007/s00394-016-1355-1. **(I.F. 5.614)**
188. Takiishi T, Cook DP, Korf H, Sebastiani G, Mancarella F, Mori Cunha JPMC, Wasserfall C, Casares N, Lasarte JJ, Steidler L, Rottiers P, **Dotta F**, Gysemans C, Mathieu C. (2017) Reversal of Diabetes in NOD Mice by Clinical-Grade Pro-Insulin and IL10 Secreting *Lactococcus Lactis* in Combination with Low-Dose Anti-CD3 Depends on the Induction of Foxp3-Positive T Cells. Diabetes; 66(2):448-459. doi: 10.2337/db15-1625. **(I.F. 9.461)**

189. Sebastiani G, Valentini M, Grieco GE, Ventriglia G, Nigi L, Mancarella F, Pellegrini S, Martino G, Sordi V, Piemonti L, **Dotta F.** (2017) MicroRNA expression profiles of human iPSCs differentiation into insulin-producing cells. *Acta Diabetol*;54(3):265-281. doi: 10.1007/s00592-016-0955-9. **(I.F. 4.280)**
190. Sebastiani G, Nigi L, Grieco GE, Mancarella F, Ventriglia G, **Dotta F.** (2017) Circulating microRNAs and diabetes mellitus: a novel tool for disease prediction, diagnosis and staging? *J Endocrinol Invest*; 40(6):591-610. doi: 10.1007/s40618-017-0611-4. **(I.F. 4.256)**
191. Solini A, Sebastiani G, Nigi L, Santini E, Rossi C, **Dotta F.** (2017) Dapagliflozin modulates glucagon secretion in a SGLT2-independent manner in murine alpha-cells. *Diabetes Metab*; 43(6):512-520. doi: 10.1016/j.diabet.2017.04.002. **(I.F. 6.041)**
192. Sebastiani G, Ventriglia G, Stabilini A, Soggi C, Morsiani C, Laurenzi A, Nigi L, Formichi C, Mfarrej B, Petrelli A, Fousteri G, BruskoTM, **Dotta F,** Battaglia M. (2017) Regulatory T-cells from pancreatic lymphnodes of patients with type-1 diabetes express increased levels of microRNA miR-125a-5p that limits CCR2 expression. *Sci Rep*; 7(1):6897. doi: 10.1038/s41598-017-07172-1 **(I.F. 4.379)**
193. Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, **Dotta F,** Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G, for the Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group. (2017) Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. *Lancet Diabetes Endocrinol*; 5(11):887-897. doi: 10.1016/S2213-8587(17)30317-0. **(I.F. 32.069)**
194. Lenzi A, **Dotta F,** Frontoni S, Cialesi R, Nicolucci A, Vaccaro K. (2017) Il progetto Cities Changing Diabetes. *L'Endocrinologo*; 18:203-207. DOI: 10.1007/s40619-017-0352-9.
195. Sebastiani G, Guarino E, Grieco GE, Formichi C, Delli Poggi C, Ceccarelli E, **Dotta F.** (2017) Circulating microRNA(miRNA) Expression Profiling in Plasma of Patients with Gestational Diabetes Mellitus Reveals Upregulation of microRNA miR-330-3p. *Front Endocrinol*; 8:345. doi: 10.3389/fendo.2017.00345 **(I.F. 5.555)**
196. Ahmann AJ, Capehorn M, Charpentier G, **Dotta F,** Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR. (2018) Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3): a 56-Week, Open-Label, Randomized Clinical Trial. *Diabetes Care*; 41(2):258-266. doi: 10.2337/dc17-0417. **(I.F. 19.112)**
197. Nigi L, Fondelli C, de Donato G, Palasciano G, Setacci C, **Dotta F.** (2018) Fighting diabetic foot ulcers- The diabetologist: A king maker of the fight. *Semin Vasc Surg.* 31(2-4):49-55. doi: 10.1053/j.semvascsurg.2018.12.003. **(I.F. 1.000)**
198. De Donato G, Pasqui E, Setacci F, Palasciano G, Nigi L, Fondelli C, Sterpetti A, **Dotta F,** Weber G, Setacci C. (2018) Acute on chronic limb ischemia: From surgical embolectomy and thrombolysis to endovascular options. *Semin Vasc Surg*; 31(2-4):66-75. doi:10.1053/j.semvascsurg.2018.12.008. **(I.F. 1.000)**
199. Culina S, Lalanne AI, Afonso G, Cerosaletti K, Pinto S, Sebastiani G, Kuranda K, Nigi L, Eugster A, Østerbye T, Maugein A, McLaren JE, Ladell K, Larger E, Beressi JP, Lissina A, Appay V, Davidson HW, Buus S, Price DA, Kuhn M, Bonifacio E, Battaglia M, Caillat-Zucman S, **Dotta F,** Scharfmann R, Kyewski B, Mallone R and the ImMaDiab Study Group (2018) Islet-reactive CD8⁺ T-cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. *Sci Immunol*; 3(20). pii:eaa04013. doi: 10.1126/sciimmunol.aa04013. **(I.F. 17.727)**

200. Catanzaro G, Besharat ZM, Chiacchiarini M, Abballe L, Sabato C, Vacca A, Borgiani P, **Dotta F**, Tesauro M, Po A, Ferretti E. (2018) Circulating microRNAs in elderly type 2 diabetic patients. Int J Endocrinol;2018:6872635. doi: 10.1155/2018/6872635. **(I.F. 3.257)**
201. Sebastiani G, Ceccarelli E, Castagna MG, **Dotta F**. (2018) G-protein coupled receptors (GPCRs) in the treatment of diabetes: Current view and future perspectives. Best Pract Res Clin Endocr Metab; 32(2):201-213. doi: 10.1016/j.beem.2018.02.005. **(I.F. 4.690)**
202. Guarino E, Delli Poggi C, Grieco GE, Cenci V, Ceccarelli E, Crisci I, Sebastiani G, **Dotta F**. (2018) Circulating MicroRNAs as biomarkers of Gestational Diabetes Mellitus: updates and perspectives. Int J Endocrinol; 2018:6380463. doi: 10.1155/2018/6380463. **(I.F. 3.257)**
203. Sebastiani G, Grieco GE, Brusco N, Ventriglia G, Formichi C, Marselli L, Marchetti P, **Dotta F**. (2018) MicroRNAs Expression Analysis of in Vitro Differentiated Human Pancreatic Islet Cells Reveals the Activation of the Pluripotency-Related MicroRNA Cluster miR-302s. Int J Mol Sci; 19(4). pii: E1170. doi: 10.3390/ijms19041170. **(I.F. 5.923)**
204. **Dotta F**, Ventriglia G, Snowwhite IV, Pugliese A. (2018) MicroRNAs: Markers of β -cell stress and autoimmunity. Curr Opin Endocrinol Diabetes; 25(4):237-245. doi: 10.1097/MED.0000000000000420. **(I.F. 3.243)**
205. Ifie E, Russell MA, Dhayal S, Leete P, Sebastiani G, Nigi L, **Dotta F**, Marjomäki V, Eizirik DL, Morgan NG, Richardson SJ. (2018) Unexpected subcellular distribution of a specific isoform of the Coxsackie and Adenovirus Receptor, CAR-SIV, in human pancreatic beta cells. Diabetologia; 61(11):2344-2355. doi: 10.1007/s00125-018-4704-1. **(I.F. 10.122)**
206. Gonzalez-Duque S, Azoury ME, Colli ML, Afonso G, Turatsinze JV, Nigi L, Lalanne AI, Sebastiani G, Carré A, Pinto S, Culina S, Corcos N, Bugliani M, Marchetti P, Armanet M, Diedisheim M, Kyewski B, Steinmetz LM, Buus S, You S, Dubois-Laforgue D, Larger E, Beressi JP, Bruno G, **Dotta F**, Scharfmann R, Eizirik DL, Verdier Y, Vinh J, Mallone R. (2018) Conventional and Neo-Antigenic Peptides Presented by β Cells Are Targeted by Circulating Naïve CD8+ T Cells in Type 1 Diabetic and Healthy Donors. Cell Metab; 28(6):946-960.e6. doi: 10.1016/j.cmet.2018.07.007. **(I.F. 27.287)**
207. Egan CG, Fondelli C, Pierantozzi E, Tripepi G, **Dotta F**, Sorrentino V. (2018) Putative endothelial progenitor cells predict long-term mortality in type-2 diabetes. Endocrine; 62(1):263-266. doi: 10.1007/s12020-018-1695-0. **(I.F. 3.633)**
208. Guay C, Kruit JK, Rome S, Menoud V, Mulder NL, Jurdzinski A, Mancarella F, Sebastiani G, Donda A, Gonzalez BJ, Jandus C, Bouzakri K, Pinget M, Boitard C, Romero P, **Dotta F**, Regazzi R. (2018) Lymphocyte-derived exosomal microRNAs promote pancreatic β -cell death and may contribute to type 1 diabetes development. Cell Metab; 29(2):348-361.e6. doi: 10.1016/j.cmet.2018.09.011. **(I.F. 27.287)**
209. Vecchio F, Lo Buono N, Stabilini A, Nigi L, Dufort MJ, Geyer S, Rancoita PM, Cugnata F, Mandelli A, Valle A, Leete P, Mancarella F, Linsley PS, Krogvold L, Herold KC, Elding Larsson H, Richardson SJ, Morgan NG, Dahl-Jørgensen K, Sebastiani G, **Dotta F**, Bosi E, the DRI_Biorepository Group, the Type 1 Diabetes TrialNet Study Group, Battaglia M. (2018) Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. JCI Insight; 3(18). pii:122146. doi: 10.1172/jci.insight122146. **(I.F. 8.315)**
210. Nigi L, Grieco GE, Ventriglia G, Brusco N, Mancarella F, Formichi C, **Dotta F***, Sebastiani G. (2018) MicroRNAs as regulators of insulin signaling: research updates and potential therapeutic perspectives in type 2 Diabetes. Int J Mol Sci;19(12). pii: E3705. doi: 10.3390/ijms19123705. **(I.F. 5.923)**
211. Grieco GE, Cataldo D, Ceccarelli E, Nigi L, Catalano G, Brusco N, Mancarella F, Ventriglia G, Fondelli C, Guarino E, Crisci I, Sebastiani G,* **Dotta F** (2018) Serum Levels of miR-148a and miR-21-5p Are Increased in Type 1 Diabetic Patients and Correlated with Markers of Bone Strength and Metabolism. Non-Coding RNA; 4(4). Pii: E37. doi: 10.3390/ncrna4040037.
212. Sesti G, Avogaro A, Belcastro S, Bonora BM, Croci M, Daniele G, Dauriz M, **Dotta F**, Formichi C,

- Frontoni S, Invitti C, Orsi E, Picconi F, Resi V, Bonora E, Purrello F. (2019) Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. *Acta Diabetol*; 56(6):605-617. doi: 10.1007/s00592-018-1271-3. **(I.F. 4.280)**
213. Solini A, Penno G, Orsi E, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Lamacchia O, Baroni MG, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. (2019) Is resistant hypertension an independent predictor of all-cause mortality in individuals with type 2 diabetes? A prospective cohort study. *BMC Med*; 17(1):83. doi: 10.1186/s12916-019-1313-x. **(I.F. 8.775)**
214. Nicolucci A, Rossi MC, Vaccaro K, Crialesi R, Rossetti S, Da Empoli S, Corsaro L, Morviducci L, Baroni MG, Frontoni S, **Dotta F**. (2019) Urban diabetes: the case of the metropolitan area of Rome. *Acta Biomed*; 90(2):209-214. doi: 10.23750/abm.v90i2.8345.
215. Marchetti P, Schulte AM, Marselli L, Schoniger E, Bugliani M, Kramer W, Overbergh L, Ullrich S, Gloyn AL, Ibberson M, Rutter G, Froguel P, Groop L, McCarthy MI, **Dotta F**, Scharfmann R, Magnan C, Eizirik DL, Mathieu C, Cnop M, Thorens B, Solimena M. (2019) Fostering improved human islet research: a European perspective. *Diabetologia*; 62(8):1514-1516. doi: 10.1007/s00125-019-4911-4. **(I.F. 10.122)**
216. Evangelista I, Nuti R, Picchioni T, **Dotta F**, Palazzuoli A. (2019) Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. *Int J Mol Sci*; 20(13). pii: E3264. doi: 10.3390/ijms20133264. Review. **(I.F. 5.923)**
217. Ventriglia G, Mancarella F, Sebastiani G, Cook FP, Mallone R, Mathieu C, Gysemans C, **Dotta F**. (2019) miR-409-3p is reduced in plasma and in islet immune infiltrates of NOD diabetic mice and is differentially expressed in type 1 diabetic patients. *Diabetologia*;63(1):124-136. doi: 10.1007/s00125-019-05026-1. **(I.F. 10.122)**
218. Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SØ, Lingvay I, Søndergaard AL, Treppendahl MB, Montanya E; PIONEER 2 Investigators. (2019) Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. *Diabetes Care*;42(12):2272-2281. doi: 10.2337/dc19-0883. **(I.F. 19.112)**
219. Grieco GE, Brusco N, Licata G, Nigi L, Formichi C, **Dotta F** and Sebastiani G. (2019) Targeting microRNAs as a Therapeutic Strategy to Reduce Oxidative Stress in Diabetes. *Int. J. Mol. Sci*;20(24):6358. doi:10.3390/ijms20246358. **(I.F. 5.923)**
220. Nigi L, Maccora C, **Dotta F**, Sebastiani G. (2019) From Immunohistological to anatomical alterations of human pancreas in Type 1 Diabetes: new concepts on the stage. *Diabetes-Metab Res Rev*; e3264. doi: 10.1002/dmrr.3264. **(I.F. 4.876)**
221. Fioravanti A, Pirtoli L, Giordano A, **Dotta F**. (2020) Crosstalk between MicroRNA and Oxidative Stress in Physiology and Pathology. *Int J Mol Sci*;21(4):1270. doi: 10.3390/ijms21041270. **(I.F. 5.923)**
222. Zampieri R, Brozzetti A, Pericolini E, Bartoloni E, Gabrielli E, Roselletti E, Lomonosoff G, Meshcheriakova Y, Santi L, Imperatori F, Merlin M, Tinazzi E, **Dotta F**, Nigi L, Sebastiani G, Pezzotti M, Falorni A, Avesani L. (2020) Prevention and treatment of autoimmune diseases with plant virus nanoparticles. *Sci Adv*;6(19):eaaz0295. doi: 10.1126/sciadv.aaz0295. **(I.F. 14.136)**
223. Cook DP, Cunha JPMCM, Martens PJ, Sassi G, Mancarella F, Ventriglia G, Sebastiani G, Vanherwegen AS, Atkinson MA, Van Huynegem K, Steidler L, Caluwaerts S, Rottiers P, Teyton L, **Dotta F**, Gysemans C, Mathieu C. (2020) Intestinal delivery of proinsulin and IL-10 via *Lactococcus lactis* combined with low-dose anti-CD3 restores tolerance outside the window of acute type 1 diabetes diagnosis. *Front Immunol*;11:1103. doi.org/10.3389/fimmu.2020.01103. **(I.F. 7.561)**
224. Nigi L, Brusco N, Grieco GE, Licata G, Krogvold L, Marselli L, Gysemans C, Overbergh L, Marchetti P, Mathieu C, Dahl-Jorgensen K, Sebastiani G, **Dotta F**. (2020) Pancreatic alpha-cells contribute together with beta-cells to CXCL10 expression in type 1 diabetes. *Front Endocrinol*;11:630. doi:

10.3389/fendo.2020.00630. eCollection 2020. (I.F. 5.555)

225. Landi C, Carleo A, Vantaggiato L, Bergantini L, d'Alessandro M, Cameli P, Sebastiani G, **Dotta F**, Bargagli E. (2020) Common molecular pathways targeted by Nintedanib in cancer and IPF: a bioinformatic study. *Pulm Pharmacol Ther*;64:101941. doi: 10.1016/j.pupt.2020.101941. Online ahead of print. PMID: 32896631. (I.F. 3.410)
226. Grieco GE, Sebastiani G, Eandi CM, Neri G, Nigi L, Brusco N, D'Aurizio R, Posarelli M, Bacci T, De Benedetto E, Fruschelli M, Orlandini M, Galvagni F, **Dotta F**, Tosi GM. (2020) MicroRNA Expression in the Aqueous Humor of Patients with Diabetic Macular Edema. *Int J Mol Sci*;21(19):E7328. doi: 10.3390/ijms21197328. (I.F. 5.923)
227. Fignani D, Licata G, Brusco N, Nigi L, Grieco GE, Marselli L, Overbergh L, Gysemans C, Colli ML, Marchetti P, Mathieu C, Eizirik DL, Sebastiani G, **Dotta F**. (2020) SARS-CoV-2 receptor Angiotensin I-Converting Enzyme type 2 (ACE2) is expressed in human pancreatic β -cells and in the human pancreas microvasculature. *Front Endocrinol*; 13;11:596898. doi: 10.3389/fendo.2020.596898. (I.F. 5.555)
228. Gentili F, Guerrini S, Mazzei FG, Monteleone I, Di Meglio N, Sansotta L, Perrella A, Puglisi S, De Filippo M, Gennaro P, Volterrani L, Castagna MG, **Dotta F**, Mazzei MA (2020) Dual energy CT in gland tumors: a comprehensive narrative review and differential diagnosis. *Gland Surg*; 9(6):2269-2282. doi: 10.21037/gs-20-543 (I.F. 2.953)
229. Grieco GE, Brusco N, Licata G, Fignani G, Formichi C, Nigi L, Sebastiani G, **Dotta F**. (2021) The landscape of microRNAs in β cell: between phenotype maintenance and protection. *Int J Mol Sci*. 22(2), 803; <https://doi.org/10.3390/ijms22020803>. (I.F. 5.923)
230. Bergantini L, Bargagli E, d'Alessandro M, Refini RM, Cameli, Galasso L, Scapellato C, Montagnani F, Scolletta S, Franchi F, Valente S, Bennett D, Sebastiani G, Frediani B, **Dotta F**. (2021) Prognostic bioindicators in severe COVID-19 patients. *Cytokine*; 141:155455. doi: 10.1016/j.cyto.2021.155455. (I.F. 3.861)
231. Bergantini L, d'Alessandro M, Cameli P, Bono C, Perruzza M, Biagini M, Pini L, Bigliuzzi C, Sestini P, **Dotta F**, Bargagli E. (2021) Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab. *Scand J Immunol*; e13031. doi: 10.1111/sji.13031. (I.F. 3.487)
232. von Herrath M, Bain SC, Bode B, Clausen JO, Coppieters K, Gaysina L, Gumprecht J, Hansen TK, Mathieu C, Morales C, Mosenzon O, Segel S, Tsoukas G, Pieber TR; Anti-IL-21–liraglutide Study Group investigators and contributors. (2021) Anti-interleukin-21 antibody and liraglutide for the preservation of β -cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Diabetes Endocrinol*;9(4):212-224. doi: 10.1016/S2213-8587(21)00019-X. (I.F. 32.069)
233. Napoli A, Sciacca L, Pintaudi B, Tumminia A, Dalfrà MG, Festa C, Formoso G, Fresa R, Graziano G, Lencioni C, Nicolucci A, Rossi MC, Succurro E, Sculli MA, Scavini M, Vitacolonna E, Bonomo M, Torlone E; STRONG Study Collaborators and the AMD-SID Diabetes and Pregnancy Study Group. (2021) Screening of postpartum diabetes in women with gestational diabetes: high-risk subgroups and areas for improvements-the STRONG observational study. *Acta Diabetol*; 58(9):1187-1197. doi: 10.1007/s00592-021-01707-9. PMID: 33842997. (I.F. 4.280)
234. Grieco GE, Fignani D, Formichi C, Nigi L, Licata G, Maccora C, Brusco N, Sebastiani G, **Dotta F** (2021) Extracellular Vesicles in immune system regulation and Type 1 Diabetes: cell-to-cell communication mediators, disease biomarkers and promising therapeutic tools. *Front. Immunol*; 12:682948. doi: 10.3389/fimmu.2021.682948. (I.F. 7.561)

235. Grieco GE, Sebastiani G, Fignani D, Brusco N, Nigi L, Formichi C, Licata G, Bruttini Marco, D'Aurizio Romina, Mathieu Chantal, Gysemans Conny, **Dotta F.** (2021) Protocol to analyze circulating small non-coding RNAs by high-throughput RNA sequencing from human plasma samples. *STAR Protocols*; 2(3):100606. doi: 10.1016/j.xpro.2021.100606.
236. Formichi C, Nigi L, Grieco GE, Maccora C, Fignani D, Brusco N, Licata G, Sebastiani G, **Dotta F.** (2021) Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases. *Int J Mol Sci.* 22(14), 7716; <https://doi.org/10.3390/ijms22147716>. **(I.F. 5.923)**
237. Faucher P, Beuvon F, Fignani D, Sebastiani G, Alfonso G, Zhou Z, Dousset B, Boitard C, **Dotta F,** Mallone R, Larger E. (2021) Immunoregulated insulinitis and slow-progressing type 1 diabetes after duodenopancreatectomy. *Diabetologia*; 64(12):2731-2740. Doi: 10.1007/s00125-021-05563-8. **(I.F. 10.122)**
238. Formichi C, Fignani D, Nigi L, Grieco GE, Brusco N, Licata G, Sabato C, Ferretti E, Sebastiani G, **Dotta F.** (2021) Circulating microRNAs signature for predicting response to GLP-1 RA therapy in type 2 diabetic patients: a pilot study. *Int J Mol Sci*; 31;22(17):9454. doi: 10.3390/ijms22179454. **(I.F. 5.923)**
239. Azoury ME, Samassa F, Buitinga M, Nigi L, Brusco N, Callebaut A, Giraud M, Irla M, Lalanne AI, Carré A, Afonso G, Zhou Z, Brandao B, Colli ML, Sebastiani G, **Dotta F,** Nakayama M, Eizirik DL, You S, Pinto S, Mamula MJ, Verdier Y, Vinh J, Buus S, Mathieu C, Overbergh L, Mallone R. (2021) CD8+ T cells variably recognize native versus citrullinated GRP78 epitopes in type 1 diabetes. *Diabetes*; 70(12):2879-2891. doi: 10.2337/db21-0259. **(I.F. 9.461)**
240. d'Alessandro M, Bergantini L, Cavallaro D, Gangi S, Cameli P, Conticini E, Siena Covid Unit, Frediani B, **Dotta F,** Bargagli E (2022) Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II. *Int J Environ Res Public Health*;19(4):2176. doi: 10.3390/ijerph19042176. PMID: 35206372. **(I.F. 3.390)**
241. Nigi L, Brusco N, Grieco GE, Fignani D, Licata G, Formichi C, Aiello E, Marselli L, Marchetti P, Krogvold L, Jorgensen KD, Sebastiani G, **Dotta F.** (2022) Increased Expression of Viral Sensor MDA5 in Pancreatic Islets and in Hormone-Negative Endocrine Cells in Recent Onset Type 1 Diabetic Donors. *Front. Immunol*;13:833141. doi: 10.3389/fimmu.2022.833141. eCollection 2022. PMID: 35359976. **(I.F. 7.561)**
242. Grieco GE, Besharat ZM, Licata G, Fignani D, Brusco N, Nigi L, Formichi C, Po A, Sabato C, Dardano A, Natali A, **Dotta F,** Sebastiani G, Ferretti E. (2022) Circulating microRNAs as clinically useful biomarkers for Type 2 Diabetes Mellitus: miRNomics from bench to bedside. *Transl Res*; S1931-5244(22)00063-9. doi: 10.1016/j.trsl.2022.03.008. PMID: 35351622. **(I.F. 7.012)**
243. Filardi T, Catanzaro G, Grieco GE, Splendiani E, Trocchianesi S, Santangelo C, Brunelli R, Guarino E, Sebastiani G, **Dotta F,** Morano S, Ferretti E. (2022) Identification and Validation of miR-222-3p and miR-409-3p as Plasma Biomarkers in Gestational Diabetes Mellitus Sharing Validated Target Genes Involved in Metabolic Homeostasis. *Int. J. Mol. Sci*; 23(8), 4276; <https://doi.org/10.3390/ijms23084276>. **(I.F. 5.923).**
244. Vantaggiato L, Cameli P, Bergantini L, d'Alessandro M, Shaba E, Carleo A, Di Giuseppe F, Angelucci S, Sebastiani G, **Dotta F,** Bini L, Bargagli E, Landi C. (2022) Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment. *Biomedicines*;10(4):761. doi:10.3390/biomedicines10040761. PMID: 35453511. **(I.F. 6.081).**
245. Dunger DB, Bruggraber SFA, Mander AP, Marcovecchio ML, Tree T, Chmura PJ, Knip M, Schulte AM, Mathieu C; INNODIA consortium. (2022) INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1

- diabetes. *Trials*;23(1):414. doi: 10.1186/s13063-022-06259-z. PMID: 35585600. **(I.F. 2.279)**.
246. Xiao P, Takiishi T, Violato NM, Licata G, **Dotta F**, Sebastiani G, Marselli L, Singh SP, Sze M, Van Loo G, Dejardin E, Gurzov EN, Cardozo AK. (2022) NF- κ B-inducing kinase (NIK) is activated in pancreatic β -cells but does not contribute to the development of diabetes. *Cell Death Dis.*;13(5):476. doi: 10.1038/s41419-022-04931-5. PMID: 35589698. **(I.F. 8.469)**.
247. Fioravanti A, Giordano A, **Dotta F**, Pirtoli L. (2022) Crosstalk between MicroRNA and Oxidative Stress in Physiology and Pathology 2.0. *Int J Mol Sci.*;23(12):6831. doi: 10.3390/ijms23126831. PMID: 35743274. **(I.F. 5.923)**
248. Tomasi M, Caproni E, Benedet M, Zanella I, Giorgetta S, Dalsass M, König E, Gagliardi A, Fantappiè L, Berti A, Tamburini S, Croia L, Di Lascio G, Bellini E, Valensin S, Licata G, Sebastiani G, **Dotta F**, Armanini F, Cumbo F, Asnicar F, Blanco-Míguez A, Ruggiero E, Segata N, Grandi G, Grandi A. (2022) Outer Membrane Vesicles From The Gut Microbiome Contribute to Tumor Immunity by Eliciting Cross-Reactive T Cells. *Front Oncol.*;12:912639. doi: 10.3389/fonc.2022.912639. eCollection 2022. PMID: 35847919. **(I.F. 5.738)**
249. Grieco GE, Brusco N, Fignani D, Nigi L, Formichi C, Licata G, Marselli L, Marchetti P, Salvini L, Tinti L, Po A, Ferretti E, Sebastiani G, **Dotta F**. (2022) Reduced miR-184-3p expression protects pancreatic β -cells from lipotoxic and proinflammatory apoptosis in type 2 diabetes via CRTCL1 upregulation. *Cell Death Discov.*;8(1):340. doi: 10.1038/s41420-022-01142-x. PMID: 35906204 **(I.F. 7.109)**
250. Brusco N, Sebastiani G, Di Giuseppe G, Licata G, Grieco GE, Fignani D, Nigi L, Formichi C, Aiello E, Auddino S, Quero G, Cefalo CMA, Cinti F, Mari A, Ferraro PM, Pontecorvi A, Alfieri S, Giaccari A, **Dotta F**, Mezza T. (2022) Intra-islet insulin synthesis defects are associated with endoplasmic reticulum stress and loss of beta cell identity in human diabetes. *Diabetologia*; 66(2):354-366. doi: 10.1007/s00125-022-05814-2. PMID: 36280617. **(I.F. 10.122)**
251. Spini A, Giometto S, Donnini S, Posarelli M, **Dotta F**, Ziche M, Tosi GM, Girardi A, Lucenteforte E, Gini R, Etminan M, Virgili G. (2022) Risk of intraocular pressure increase with intravitreal injections of Vascular Endothelial Growth Factor Inhibitors: a cohort study. *Am J Ophthalmol*: 248:45-50. doi: 10.1016/j.ajo.2022.11.015. PMID: 36410468 **(I.F. 5.488)**
252. Orsi E, Solini A, Penno G, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Lamacchia O, Haxhi J, Nicolucci A, Pugliese G; Renal Insufficiency and Cardiovascular Events (RIACE) Study Group. (2022) Body mass index versus surrogate measures of central adiposity as independent predictors of mortality in type 2 diabetes. *Cardiovasc Diabetol*;21(1):266. doi: 10.1186/s12933-022-01706-2. PMID: 36461034. **(I.F. 8.949)**
253. Ambroselli D, Masciulli F, Romano E, Catanzaro G, Besharat ZM, Massari MC, Ferretti E, Migliaccio S, Izzo L, Ritieni A, Grosso M, Formichi C, **Dotta F**, Frigerio F, Barbiera E, Giusti AM, Ingallina C, Mannina L. (2023) New Advances in Metabolic Syndrome, from Prevention to Treatment: The Role of Diet and Food. *Nutrients*, 15(3), 640. <https://doi.org/10.3390/nu15030640>. **(I.F. 6.706)**
254. Suomi T, Starskaia I, Kalim UU, Rasool O, Jaakkola MK, Grönroos T, Välikangas T, Brorsson C, Mazzone G, Bruggraber S, Overbergh L, Dunger D, Peakman M, Chmura P, Brunak S, Schulte AM, Mathieu C, Knip M, Lahesmaa R, Elo LL; INNODIA Consortium. (2023) Gene expression signature predicts rate of type 1 diabetes progression. *EBioMedicine*;92:104625. doi: 10.1016/j.ebiom.2023.104625. Online ahead of print. PMID: 37224769. **(I.F.11.205)**
255. Besharat ZM, Trocchianesi S, Verrienti A, Ciampi R, Cantara S, Romei C, Sabato C, Noviello TMR, Po A, Citarella A, Caruso FP, Panariello I, Gianni F, Carpino G, Gaudio E, Chiacchiarini M, Masuelli L, Sponziello M, Pecce V, Ramone T, Maino F, **Dotta F**, Ceccarelli M, Pezzullo L, Durante C, Castagna MG, Elisei R, Ferretti E. (2023) Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients. *J Endocrinol Invest*; doi: 10.1007/s40618-023-02115-2. Online ahead of print. **(I.F. 4.256)**

256. Fignani D, Pedace E, Licata G, Grieco GE, Aiello E, de Luca C, Marselli L, Marchetti P, Sebastiani G, **Dotta F.** (2023) Angiotensin I-converting enzyme type 2 expression is increased in pancreatic islets of type 2 diabetic donors. *Diabetes Metab Res Rev*:e3696. doi: 10.1002/dmrr.3696. Online ahead of print. PMID: 37466955 **(I.F. 4.876)**
257. Sassi G, Licata G, Ventriglia G, Wouters A, Lemaitre P, Seurinck R, Mori A, Grieco GE, Bissenova S, Ellis D, Caluwaerts S, Rottiers P, Vandamme N, Mathieu C, **Dotta F,** Gysemans C, Sebastiani G. (2023) A plasma miR-193b-365 signature combined with age and glycemic status predicts response to *Lactococcus lactis*-based antigen-specific immunotherapy in new-onset type 1 diabetes. *Diabetes*:db220852. doi: 10.2337/db22-0852. Online ahead of print. PMID: 37494666 **(I.F. 9.461)**
258. Besharat ZM, Trocchianesi S, Verrienti A, Ciampi R, Cantara S, Romei C, Sabato C, Noviello TMR, Po A, Citarella A, Caruso FP, Panariello I, Gianno F, Carpino G, Gaudio E, Chiacchiarini M, Masuelli L, Sponziello M, Pecce V, Ramone T, Maino F, **Dotta F,** Ceccarelli M, Pezzullo L, Durante C, Castagna MG, Elisei R, Ferretti E. (2023) Correction: Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients. *J Endocrinol Invest*. doi: 10.1007/s40618-023-02172-7. Online ahead of print. PMID: 37563447. **(I.F. 4.256)**
259. Nigi L, Iraci Sareri G, Cataldo D, **Dotta F.** (2023) 12-month efficacy of advanced hybrid-closed loop system in adult type 1 diabetic patients. *Diabetes Technol Ther*; doi: 10.1089/dia.2023.0319. Online ahead of print. PMID: 37902713. **(I.F. 5.4)**
260. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med*; 389(24):2221-2232. doi: 10.1056/NEJMoa2307563. PMID: 37952131 **(I.F. 176.08)**
261. Nigi L, Laiho JE, Hyöty H, **Dotta F.** (2023) Editorial: The contribution of viruses and innate immune system in the pathogenesis of type 1 diabetes. *Front Endocrinol (Lausanne)*; 14:1335716. doi: 10.3389/fendo.2023.1335716. PMID: 38161972 **(I.F. 5.2)**
262. Cantley J, Eizirik DL, Latres E, Dayan CM, Sims EK, Mathieu C, Eizirik D, Atkinson MA, Richardson J, Kaestner KH, Brissova M, Evans-Molina C, Rodriguez-Calvo T, **Dotta F,** Todd J, Pasquali L, Mallone R, Shalev A, Lickert H, Mirmira RG; Pugliese A, Forbes S, Otonkoski T, Winkel L, Herold KC, Senior P, Brehm MA, Oram RA, Parks S, Boughton CK. (2023) Islet cells in human type 1 diabetes: from recent advances to novel therapies – a symposium-based roadmap for future research. *J Endocrinol*; 259(1): e230082. doi: 10.1530/JOE-23-0082. **(I.F. 4)**
263. Dalmiglio C, Bombardieri A, Mattii E, Sestini F, Fioravanti C, Castagna MG, Fiorini M, **Dotta F,** Cantara S. (2024) Analytical performance of free testosterone calculated by direct immunoluminometric method compared with the Vermeulen equation: results from a clinical series. *Hormones (Athens)*; 23(2):313-319 doi: 10.1007/s42000-023-00522-x. PMID: 38177558 **(I.F. 3.2)**
264. Hendriks AEJ, Marcovecchio ML, Besser REJ, Bonifacio E, Casteels K, Elding Larsson H, Gemulla G, Lundgren M, Kordonouri O, Mallone R, Pociot F, Szybowska A, Toppari J, Berge TVD, Ziegler AG, Mathieu C, Achenbach P; INNODIA consortium, the Fr1da Study Group and the GPPAD Study Group. (2024) Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes. *Diabetes Metab Res Rev*;40(2):e3777. doi: 10.1002/dmrr.3777. PMID: 38375753 **(I.F. 4.876)**
265. Formichi C, Baronti W, de Gennaro G, Cerrai Ceroni M, Nigi L, Rizzo L, **Dotta F.** (2024) Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient? *J Endocrinol Invest*. doi: 10.1007/s40618-024-02369-4. Online ahead of print. PMID: 38683498 **(I.F. 3.9)**
266. Graziani V, Suprani T, Di Bartolo P, Marchetti F; TransiDEA study group. (2024) From pediatric to adult care: a survey on the transition process in type 1 diabetes mellitus and the diabetes services in

- Italy. *Acta Diabetol*;61(8):1069-1076. doi: 10.1007/s00592-024-02268-3. Epub 2024 May 3. PMID: 38700547. **(I.F. 4.280)**
267. Sajiir H, Wong KY, Müller A, Keshvari S, Burr L, Aiello E, Mezza T, Giaccari A, Sebastiani G, Dotta F, Ramm GA, Macdonald GA, McGuckin MA, Prins JB, Hasnain SZ. (2024) Pancreatic beta-cell IL-22 receptor deficiency induces age-dependent dysregulation of insulin biosynthesis and systemic glucose homeostasis. *Nature Commun.*; 15(1):4527. doi: 10.1038/s41467-024-48320-2. PMID: 38811550 **(I.F. 17.7)**
268. Sebastiani G, Grieco GE, Bruttini M, Auddino S, Mori A, Toniolli M, Fignani D, Licata G, Aiello E, Nigi L, Formichi C, Fernandez-Tajes J, Pugliese A, Evans-Molina C, Overbergh L, Tree T, Peakman M, Mathieu C, **Dotta F**; INNODIA investigators. (2024) A set of circulating microRNAs belonging to the 14q32 chromosome locus identifies two subgroups of individuals with recent-onset type 1 diabetes. *Cell Rep Med.*;5(6):101591. doi: 10.1016/j.xcrm.2024.101591. PMID: 38838677 **(I.F. 11.7)**
269. Armenteros JJA, Brorsson C, Johansen CH, Banasik K, Mazzoni G, Moulder R, Hirvonen K, Suomi T, Rasool O, Bruggraber SFA, Marcovecchio ML, Hendricks E, Al-Sari N, Mattila I, Legido-Quigley C, Suvitaival T, Chmura PJ, Knip M, Schulte AM, Lee JH, Sebastiani G, Grieco GE, Elo LL, Kaur S, Pociot F, **Dotta F**, Tree T, Lahesmaa R, Overbergh L, Mathieu C, Peakman M, Brunak S; INNODIA investigators (2024) Multi-omics analysis reveals drivers of loss of β -cell function after newly diagnosed autoimmune type 1 diabetes: An INNODIA multicenter study. *Diabetes Metab Res Rev.*;40(5):e3833. doi: 10.1002/dmrr.3833. PMID: 38961656 **(I.F. 4.876)**
270. Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, Lingvay I, Colhoun HM, Plutzky J, Kosiborod MN, Hovingh GK, Hardt-Lindberg S, Frenkel O, Weeke PE, Rasmussen S, Goudev A, Lang CC, Urina-Triana M, Pietilä M, Lincoff AM; SELECT Trial Investigators. (2024) Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. *Lancet*;404(10454):773-786. doi: 10.1016/S0140-6736(24)01498-3. PMID: 39181597 **(I.F. 98.4)**
271. Silvestri C, Stasi C, Profili F, Bartolacci S, Sessa E, Tacconi D, Villari L, Carrozzi L, **Dotta F**, Bargagli E, Donnini S, Masotti L, Rasero L, Lavorini F, Pistelli F, Chimera D, Sorano A, Pacifici M, Milli C, Voller F, Sprint Study Group. (2024) Retrospective Study on the Features and Outcomes of a Tuscany COVID-19 Hospitalized Patients Cohort: Preliminary Results. *J Clin Med*;13(16):4626. doi: 10.3390/jcm13164626. PMID: 39200770 **(I.F. 3)**.
272. Nigi L, Simon Batzibal MLA, Cataldo D, Dotta F. 12-Month Time in Tight Range Improvement with Advanced Hybrid-Closed Loop System in Adults with Type 1 Diabetes. *Diabetes Ther.* 2024 Dec;15(12):2557-2568. doi: 10.1007/s13300-024-01656-w. Epub 2024 Sep 30. PMID: 39347899; PMCID: PMC11561210. **(I.F. 2.8)**
273. Auddino S, Aiello E, Grieco GE, Dotta F, Sebastiani G. A three-layer perspective on miRNA regulation in β cell inflammation. *Trends Endocrinol Metab.* 2024 Nov 11:S1043-2760(24)00257-1. doi: 10.1016/j.tem.2024.10.002. Epub ahead of print. PMID: 39532586. **(I.F. 11.4)**